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 Arachidonic acid (ARA) is a long chain polyunsaturated fatty acid that is 
routinely added to infant formula with docosahexaenoic acid (DHA) to support 
neonatal growth and development.  Optimal levels of ARA in formula remain to 
be determined and are based largely on mean worldwide values in breast milk.  
The objective of this dissertation research was to determine the role of dietary 
ARA in neonatal development and to evaluate the optimal level in formula to 
support proper growth and development.  Two studies with neonatal domestic 
pigs were carried out to achieve this objective. 
 The purpose of the first study was to determine the effect of the dietary 
ARA level on growth, clinical chemistry and immune function, and on tissue 
ARA and DHA accretion.  On day 3 of age, formula-reared (FR) piglets were 
assigned to 1 of 6 milk replacer formulas containing ARA/DHA as follows (% 
fatty acid (FA)/FA): (a1) 0.1/1.0; (a2) 0.53/1.0; (a3-d3) 0.69/1.0; (a4) 1.1/1.0; 
(d2) 0.67/0.62; (d1) 0.66/0.33.  No significant differences were observed 
among the FR groups for growth, hemogram, clinical chemistry or measures of 
immune status.  Heart and liver ARA were responsive to dietary ARA while 
brain and retina were not.  Heart ARA was particularly sensitive to dietary 
ARA.  In the second study, we evaluated two ARA oils for potential use in 
infant formula compared with a third, commercially available ARA oil.  Diets 
 were fed on days 3 – 22 of life and supplied ARA at 0.64% FA and DHA at 
0.34% FA.  We observed no toxicological effects or differences in growth, and 
concluded that the experimental ARA oils are safe and bioequivalent to the 
commercially available ARA source. 
 Overall, results from this dissertation research suggest that the dietary 
ARA level has a negligible effect on growth and development of the central 
nervous and immune systems when DHA is supplied near the high end of 
human breast milk levels (1% FA).  The unique responsiveness of the heart to 
dietary ARA level revealed that ARA accretion is limited by dietary supply.  
Further investigations are warranted to determine the significance of ARA 
status on immediate and long term cardiac physiology. 
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CHAPTER ONE 
 
NEGLIGIBLE EFFECT OF DIETARY ARACHIDONIC ACID (ARA) LEVELS 
ON GROWTH, CLINICAL CHEMISTRY AND IMMUNE FUNCTION IN 
DOMESTIC PIGLETS* 
 
Abstract 
In the U.S., infant formulas with arachidonic acid (ARA) and 
docosahexaenoic acid (DHA) contain these long chain polyunsaturated fatty 
acids (LCPUFA) in a 2:1 ratio and comprising about 0.67% and 0.32% of total 
fatty acids (FA).  Higher levels of dietary DHA appear to provide some 
advantages in visual or cognitive performance.  This study evaluated the effect 
of the dietary ARA level on growth, clinical chemistry and immune function 
when DHA is at the high end of human breast milk levels.  On day 3 of age, 
formula-reared (FR) piglets were matched for weight and assigned to one of 
six milk replacer formulas.  Diets varied in the ratio of ARA/DHA as follows (% 
FA/FA): (a1) 0.1/1.0; (a2) 0.53/1.0; (a3-d3) 0.69/1.0; (a4) 1.1/1.0; (d2) 
0.67/0.62; (d1) 0.66/0.33.   A seventh group was maternal-reared (MR) and 
remained with the dam during the study.  Blood collection and body weight 
measurements were performed weekly and piglets were sacrificed on day 28 
of age.  No significant differences were found among any of the FR groups for 
formula intake, growth, hemogram, clinical chemistry or immune status 
measurements.  Mean body weight of MR pigs on day 28 of age was 2.4 kg 
less than the FR pigs.  A few differences in clinical chemistry and immune 
 
 
*Tyburczy, C., Kothapalli, K. S. D., Park, W. J., Blank, B. S., Liu, Y.-C., Nauroth, J. M., 
Zimmer, J.P., Salem, Jr., N., Brenna, J. T. (2010) Food Chem Toxicol, submitted. 
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status between MR and FR groups likely reflected a difference in growth rate.  
We conclude that the dietary ARA level has a negligible effect on growth, 
clinical chemistry and immune function in domestic piglets when DHA is 
supplied at 1.0% FA, and confirm that DHA has no effect when ARA is at 
0.66%. 
 
Introduction 
Arachidonic acid (ARA, 20:4n-6) is a natural component of human 
breast milk and is routinely added to infant formulas along with 
docosahexaenoic acid (DHA, 22:6n-3).  Both are long chain polyunsaturated 
fatty acids (LCPUFA) that contribute to normal growth and development during 
the perinatal period, serving as essential structural components of central 
nervous tissue and precursors for lipid signaling molecules (1,2).  In the U.S., 
conventional infant formulas include ARA and DHA at target levels of 0.66% 
and 0.32% of total fatty acids (FA), respectively.  World-wide levels in breast 
milk prove more variable, however, comprising 0.47 ± 0.13% (range 0.24 – 
1.0%) and 0.32 ± 0.22% (range 0.06 – 1.4%) of total FA (3).  The range of 
ARA and DHA in breast milk is likely due primarily to maternal diet.  As a guide 
for infant formulas, the world-wide variability in breast milk levels presents a 
challenge for optimizing the FA composition of formula to support proper 
development of the infant central nervous and immune systems. 
Clinical studies in human infants that are designed to determine the 
optimal level of LCPUFA in formula are limited in the toxicological parameters 
that they can measure.  Here, studies have demonstrated visual and cognitive 
benefits of LCPUFA intake to formula-fed infants, compared with non-
supplemented formula-fed infants (4).  For these studies, DHA was 
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investigated in the range of 0.2 – 1.0% of total FA, and results provide 
convincing evidence for maintaining DHA in formula at levels ≥ 0.3%.  Levels 
of DHA up to 1.0% of total FA have been reported as generally safe for infants 
1-6 months of age, while preclinical studies in weanling rats report no adverse 
effects on growth or development with DHA intakes up to 5900 mg/kg/d (5).  
On the other hand, studies addressing the level of ARA or the ARA/DHA ratio 
in formula are rare and limited to only a few preclinical studies where ARA and 
DHA were fed together in a 2:1 ratio (6-8).  ARA and DHA are thought to 
compete for tissue incorporation, including liver (9) and may influence each 
other’s physiological effects (10,11).  The effect of this competition on 
functional outcomes associated with ARA, particularly in the context of high 
dietary DHA, remains unclear.    
The absence or presence of DHA and ARA in piglet formula can 
modulate neonatal immune responses (12), but dose-response effects have 
not been examined.  Three immune status measures were included in this 
study to examine immunization response, immune maturation and 
inflammatory state.  These measures were selected to be applicable to both 
piglet and infant immune function.  For example, if the dietary treatments 
modulate immunization response in the piglets, clinical trials could then follow-
up by monitoring vaccine responses in infants.  For immune maturation, it is 
known that early life serum IgG and IgA concentrations increase as 
exogenous antigen exposures accumulate (13).  This applies to piglets as well 
because gnotobiotic pigs have significantly lower serum IgA and IgG 
compared to conventionally-raised pigs with a typical gut microflora (14).  
Thus, serum IgA or IgG may provide a novel but rough comparison of net 
immunological maturation across dietary treatments.  Finally, higher intakes of 
3
DHA are anti-inflammatory in humans and animal models (2).  It is not known 
if increasing the dietary ratio of ARA to DHA in piglet formula could produce a 
relatively pro-inflammatory state.  A wide range of clinical and subclinical 
inflammatory events can trigger the liver to produce serum acute phase 
proteins.  Three different acute phase proteins, highly-sensitive C-reactive 
protein, serum amyloid A and haptoglobin (hsCRP, SAA and Hp), were 
monitored because they can differ in sensitivity to detect systemic 
inflammation (15). 
To date, there have been no ARA dose-response studies against a 
background of high dietary DHA in rapidly growing, suckling animals.  Our 
objective was to determine the effect of the dietary ARA level on growth, 
clinical chemistry and immune function when DHA is constant and near the 
high end of human breast milk levels (i.e. 1.0% total FA).  A dose-response for 
DHA was also included with normal levels of ARA.  Domestic piglets were 
used because of their metabolic similarities to humans as well as their rates of 
perinatal brain growth (16).  Human breast milk is considered the gold 
standard of nutrition for the developing infant, and because the FA 
composition and nutrient content of sow milk closely mimics human breast 
milk, an additional group of piglets were included as a maternal-reared (MR) 
reference treatment. 
 
Materials and methods 
Animals 
All procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Cornell University.  Domestic piglets were 
selected for gender and weight from 15 sows at the swine facility at Cornell 
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University.  One day before the scheduled, term farrowing date, pregnant 
sows were injected with 2 cc of Lutalyse (Pfizer Animal Health, Kalamazoo, 
MI) to obtain a block of piglets with the same birth date.  Piglets were 
processed according to standard facility practices (i.e. intramuscular injection 
of iron dextran (100 mg) and penicillin G (½ cc), tooth clip, tail dock, ear notch) 
and remained with the sow until day 3 of age, at which time they were 
matched for weight and assigned to one of six milk replacer diets  (n=8 per 
diet).  The formula-reared (FR) piglets were housed individually in raised metal 
cages and maintained on a 16/8 hr light/dark cycle.  MR piglets remained with 
their dam at the swine facility for the duration of the study.   
 
Diets 
Milk replacer formula consisting of 60% experimental diet (Research 
Diets, Inc., New Brunswick, NJ) and 40% Birthright baby pig milk replacer 
(Ralco Nutrition, Inc., Marshall, MN) was fed to FR piglets on days 3 – 28 of 
age.  Diets were designed to meet or exceed nutrient requirements for growing 
pigs 3 – 5 kg in body weight (17).  The nutrient composition of the Birthright 
baby pig milk replacer is published elsewhere (18).  A detailed ingredient 
composition and nutrient analysis of the experimental diets is listed in Table 
1.1.  The four-oil blend consisting of palmolein, soy, coconut and high oleic 
sunflower oils that is currently used in the commercial human infant formula 
Enfamil (Mead-Johnson Nutrition, Evansville, IN) made up the base oil for the 
experimental diets.  LCPUFA were supplied by ARASCO and DHASCO 
single-cell oils (Martek Biosciences, Corp., Columbia, MD), derived from the 
marine micro-algae C. cohnii and the fungus M. alpina, respectively.  As fed, 
the milk replacer formula had a caloric density of 0.7 kcal/ml and a 
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macronutrient analysis as follows (gram %): protein 26.7%, fat 21.9% and 
carbohydrate 38.9%.  Formulas were constituted daily by adding 1.0 L water to 
180 g dry diet and stored at 3-4˚C until feeding.  Fresh formula was provided 
three times per day in stainless steel bowls fixed into the cage doors and 
water was offered ad libitum.  FR piglets were fed at 80% ad libitum intake, 
based on pilot data, to moderately exceed growth rates of the MR piglets (19).  
Formula intakes were recorded daily. 
The FA composition of the milk replacer formula and sow milk (day 14 
in lactation) is presented in Table 1.2.  Diets varied in the ratio of ARA/DHA as 
follows (% FA/FA): (a1) 0.1/1.0; (a2) 0.53/1.0; (a3-d3) 0.69/1.0; (a4) 1.1/1.0; 
(d2) 0.67/0.62; (d1) 0.66/0.33 (conventional infant formula), and corresponded 
to the following ARA/DHA intakes (mg/mg per 100 kcal of formula): (a1) 
3.2/45.3; (a2) 24.0/45.3; (a3-d3) 31.3/45.3; (a4) 49.0/45.3; (d2) 30.4/28.1; (d1) 
29.9/14.9.  Diets a1-a4 are a dose-response for ARA against DHA constant at 
1.0%, while diets d1-d3 are a dose-response for DHA against ARA constant at 
0.67%.  Diets d2 and a4 contain ARA and DHA at a 1:1 ratio, but at two 
different dietary levels, 0.67% and 1.0%, respectively.  FA composition of the 
diets and sow milk was determined by gas chromatography.  FA methyl esters 
(FAME) were prepared from dry diet and 50 μl sow milk by the one-step 
hydrolysis, extraction, and methylation procedure (20) as modified previously 
(21) and quantified on a 5890 Series II gas chromatograph (Hewlett-Packard, 
Palo Alto, CA) equipped with a BPX70 fused silica column (25 m x 0.22 mm 
i.d. x 0.25 μm film; SGE Inc., Austin, TX).  A detailed protocol for the One-step 
method is presented in Appendix II. An equal weight FAME mixture was used 
to verify response factors.  FAME were structurally identified by 
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covalent-adduct chemical ionization mass spectrometry on a Saturn 2000 
mass spectrometer (Varian, Inc., Walnut Creek, CA) (22). 
 
Sampling 
Body weights measurements were taken weekly.  Non-fasted blood 
samples were collected from the anterior vena cava into vacutainer tubes (BD, 
Franklin Lakes, NJ) on days 3, 7, 14 and 21 of age.  Overnight-fasted blood 
samples were collected on day 28 of age, and an additional aliquot of blood 
was collected into EDTA-containing tubes for hemogram analysis.  Serum was 
harvested by centrifuging clotted blood at 2800 rpm and 4˚C for 10 min.  
Piglets were sacrificed on day 28 of age via an intravenous injection of Fatal 
Plus (1 ml/4.54 kg body weight; Vortech Pharmaceuticals, Dearborn, MI, USA) 
followed by exsanguination.  Organs were removed, weighed, and samples 
flash frozen within 10 min of cessation of heart beat. 
 
Clinical chemistry and hemogram analysis 
Serum and EDTA-blood from 28-day-old piglets were delivered to the 
Animal Health Diagnostic Center (College of Veterinary Medicine, Cornell 
University) for analysis of clinical chemistry and hemogram parameters. 
 
Mycoplasma hyopneumoniae vaccination 
 Piglets were vaccinated against M. hyopneumoniae (RespiSure-One, 
Pfizer Animal Health, Kalamazoo, MI) on day 7 of age.  Serum samples 
collected on days 21 and 28 of age (14 and 21 days post-immunization) were 
analyzed for antibodies to M. hyopneumoniae.  M. hyopneumoniae immunity 
protects against a common respiratory disease in swine that is not endemic at  
7
  
 
Table 1.1. Ingredient composition and nutrient analysis of experimental diets 
Composition Content 
Dietary ingredient, % dry matter  
    Dried skim milk 55.0 
    Oil blend 23.9 
    Calcium sodium caseinate 9.6 
    Vitamin mix1 4.8 
    Mineral mix2 4.8 
    Xanthan gum 1.4 
    Methionine, DL 0.5 
Nutrient analysis, % kcal  
    Protein 24.3 
    Carbohydrate 28.7 
    Fat 47.0 
 
1The mineral mix contained (g/kg): 257.8 sucrose, 615.8 dibasic calcium 
phosphate, 106.7 sodium chloride, 11.8 ferric citrate, 4.0 zinc carbonate, 3.4 
magnesium oxide, 0.4 cupric carbonate, 0.2 manganous carbonate, 0.1 
potassium iodate, 0.01 sodium selenite. 
 
2The vitamin mix contained (g/kg): 910.1 sucrose, 75.0 choline bitartrate, 6.2 
vitamin E acetate (50%), 3.4 vitamin A acetate (500,000 IU/g), 1.5 vitamin D3 
(100,000 IU/g), 1.3 vitamin B12 (0.1% mannitol), 0.9 pantothenic acid (d, 
calcium), 0.9 niacin, 0.4 biotin (1%), 0.1 riboflavin, 0.1 thiamine HCl 0.03 
menadione sodium bisulfite, 0.01 folic acid, 0.01 pyridoxine HCl. 
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Table 1.2. FA composition of milk replacer formulas and sow milk1
Diet a1 a2 a3-d3 a4 d2 d1 MR 
ARA/DHA 0.1/1.0 0.53/1.0 0.69/1.0 1.1/1.0 0.67/0.62 0.66/0.33 0.74/0.01 
 FA (% total FA) 
Σ SFA + MUFA 79.86 79.94 79.43 79.18 80.02 80.02 83.94 ± 3.16 
ARA 0.09 0.53 0.69 1.06 0.67 0.66 0.74 ± 0.02 
DHA 1.00 1.02 1.01 1.04 0.62 0.33 0.01 ± 0.01 
Σ n-6 17.50 17.52 17.95 18.15 17.76 18.00 15.21 ± 3.08 
Σ n-3 2.53 2.43 2.49 2.51 2.10 1.86 0.71 ± 0.04 
18:2n-6 17.25 16.83 17.11 16.93 16.90 17.19 12.05 ± 2.98 
18:3n-3 1.53 1.41 1.48 1.47 1.48 1.53 0.57 ± 0.06 
18:2n-6/18:3n-3 11.3 12.0 11.6 11.5 11.4 11.3 21.1 
 
1Milk from two sows taken on day 14 of lactation; MR piglets remained with the sow for the duration of the study. 
 
2SFA, saturated FA; MUFA, monounsaturated FA. 
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the Cornell University swine facility or the Large Animal Research and 
Teaching Unit.  Respisure-One is intended to induce a protective antibody titer 
14-21 days after a single injection at day 7 (23). 
 
Enzyme linked immunosorbant assays (ELISA) 
Serum samples were thawed immediately prior to use.  Commercial 
ELISA kits were used to quantify serum total IgA, IgG, and IgM, (Bethyl 
Laboratories, Montgomery, TX) and the acute phase proteins: hsCRP and Hp 
(Kamiya Biomedical Company, Seattle, WA), and SAA (Tri-Delta Development 
LTD, Ireland) following the manufacturer’s instructions.  Antibodies to M. 
hyopneumoniae were detected by semi-quantitive ELISA following the 
manufacturer’s instructions (HerdChekTM, IDEXX Laboratories, Westbrook, 
ME).  Serum samples were tested in duplicate, with the exception of the Hp 
ELISA in which two different serum dilutions (1:10,000 and 1:20,000) were 
averaged. 
 
Statistical analysis 
Statistical analysis was carried out using the Fit Model platform of JMP 
(2008 SAS Institute, 8.0) to fit mixed models.  Fixed effects were diet, gender, 
day 3 of age body weight and the full factorial of interactions.  Interaction 
effects were considered significant at P < 0.10 and fixed effects at P < 0.05.  
For each parameter analyzed, effects not considered significant were removed 
from the final model.  Random effects were litter and animal nested within litter 
for repeated measures of body weight.  Significance of pairwise comparisons 
was determined using the Student’s t-test.  Linear regression analysis was 
performed to determine the relationship between clinical chemistry and 
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hemogram parameters and the dietary content of ARA and DHA.  Values are 
reported as means ± SD.   
 
Results 
Clinical observations, feed intake and growth  
All 56 piglets remained on the study until day 28 of age, and only one 
piglet (diet a3-d3) required antibiotic treatment during the study, which was 
due to developing an abscess on its toe.  Total formula intakes averaged 51.6 
± 0.1 L and were unaffected by diet.  There were small differences in body 
weight among the FR groups on day 7 of age with a1 piglets (0.1/1.0% 
ARA/DHA) weighing significantly less than all other FR groups, as shown in 
Figure 1.1.  By day 14 of age, this difference in body weight was abolished 
and the a1 piglets showed body weights similar to all other FR groups for the 
remainder of the study.  Further, there were no differences in body weight 
among any of the FR groups on days 14, 21 or 28 of age.  The MR group was 
heavier than the FR groups on day 7 of age, but the MR group weighed the 
least at days 21 and 28 of age.  On day 28 of age, mean weight for all FR 
piglets was 10.3 ± 0.6 kg, while MR piglets weighed 7.9 ± 0.7 kg. 
Relative organ weights (weight as a percentage of final body weight) 
from piglets on day 28 of age are presented in Figure 1.2 (Panel A).  There 
were no differences in relative organ weights among any of the FR groups; 
however, compared with the MR group, FR piglets had greater relative weights 
for liver.  Absolute brain weights (Figure 1.2, Panel B) were similar across all 
diets, while relative brain weight was greatest for MR piglets compared with 
the FR groups.   
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Figure 1.1. Body weight measurements by piglet day of age.  Values (means ± 
SD) not sharing a common letter are significantly different (P < 0.05); * values 
significantly different between maternal-reared (MR) piglets and all 
formula-reared groups (P < 0.05). 
 
Hemogram and clinical chemistry 
 Data for the hemogram analysis are presented in Figure 1.3.  Mean 
values for hematocrit and red blood cell count were 35 ± 4% and 6.7 ± 0.6  
mill/μl, respectively, and were unaffected by diet.  Small differences were 
apparent among the FR groups for mean cell hemoglobin and red cell 
distribution width.  There were no differences among the FR groups for 
hemoglobin, mean cell hemoglobin concentration and mean cell volume; 
however, FR groups significantly differed from the MR piglets for these values 
with the MR group presenting a more favorable hemogram status.  For all 
piglets, platelet count averaged 1022 ± 259 thou/μl and was unaffected by 
treatment. 
 Total white blood cell count averaged 9.8 ± 3.3 thou/μl and was 
unaffected by diet.  There were no differences among diets for segmented 
neutrophils, monocytes, eosinophils or basophils (data not presented).  
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Lymphocyte count was highest in a4 piglets; however, the range of means (4.9 
– 6.8 thou/μl) across all diets was within the normal reference range for 
nursery piglets (24).  
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Figure 1.2. Relative organ (A) and absolute brain (B) weights from piglets on 
day 28 of age. *Values (means ± SD) significantly different between 
maternal-reared (MR) piglets and all formula-reared groups (P < 0.05). 
 
Consistent with the hemogram analysis, only small differences in the 
clinical chemistry profile were apparent among the FR groups, including 
values for serum chloride, albumin and globulin, as listed in Table 1.3.  While 
statistical differences were observed for these parameters, values fall within 
the normal reference ranges for nursery piglets (25,26) and thus were likely to 
be biologically insignificant.  Also consistent with the hemogram analysis, 
clinical chemistry values related to serum iron status (i.e. serum iron, total iron 
binding capacity and percent saturation) were different between MR and FR 
groups and indicated a more positive serum iron status for the MR piglets.  
Additional serum clinical chemistry parameters that were not significantly 
different among any of the dietary treatments were creatinine, aspartate 
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dietary treatment.  Serum IgA levels in the MR piglets were significantly higher 
on day 28 of age than all FR groups (P < 0.001), but IgA levels did not differ 
among any of the FR groups.  Serum IgM and IgG levels on day 28 of age 
were unaffected by diet.  There were minor differences in SAA levels on day 7 
Table 1.4 presents a summary of immune status measurements.  All 
piglets were negative for antibodies to M. hyopneumoniae on day 28 of age 
and there were no significant differences in titers to M. hyopneumoniae by  
Immunization response & measurements of immune status 
aminotransferase, glutamate dehydrogenase, alkaline phosphatase, 
gamma-glutamyl transferase, sorbitol dehydrogenase and creatinine kinase. 
 
Figure 1.3. Profile of hemogram parameters from piglets on day 28 of age.  
Values (means ± SD) not sharing a common letter are significantly different (P 
< 0.05); * values significantly different between maternal-reared (MR) piglets 
and all formula-reared groups (P < 0.05).  MCH, mean cell hemoglobin; 
MCHC, mean cell hemoglobin concentration; MCV, mean cell volume; MPV, 
mean platelet volume; MR, maternal-reared; RDW, red cell distribution width. 
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Table 1.3. Summary of clinical chemistry profiles from piglets on day 28 of age1,2
Diet a1 a2 a3-d3 a4 d1 d2 MR   
ARA/DHA 
(%, FA/FA) 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
Glucose (mg/dL) 158 ± 30 152 ± 32 159 ± 27 156 ± 33 162 ± 27 169 ± 32 131 ± 8 NS 
BUN (mg/dL) 6 ± 1 6 ± 2 6 ± 2 6 ± 2 6 ± 1 6 ± 2 8 ± 1 NS 
Creatinine (mg/dL) 0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 NS 
Total protein (g/dL) 5.2 ± 0.3 5.0 ± 0.3 5.0 ± 0.3 5.1 ± 0.4 5.0 ± 0.3 5.3 ± 0.3 4.7 ± 0.3 NS 
Total bilirubin (mg/dL) 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.2 NS 
Na (mEq/L) 143 ± 4 143 ± 3 144 ± 3 145 ± 3 143 ± 2 144 ± 2 141 ± 2 NS 
K (mEq/L) 5.9 ± 0.7 6.2 ± 0.7 6.2 ± 0.8 6.2 ± 0.8 5.9 ± 0.8 5.9 ± 0.5 5.2 ± 0.9 NS 
Cl (mEq/L) 100 ± 2c 101 ± 1bc 102 ± 2ab 101 ± 2ab 100 ± 2bc 100 ± 2c 105 ± 2a 0.02 
Bicarbonate (mEq/L) 19 ± 5 21 ± 5 20 ± 4 20 ± 6 21 ± 4 19 ± 5 23 ± 2 NS 
Ca (mg/dL) 11.3 ± 0.7 11.3 ± 0.6 11.1 ± 0.5 11.2 ± 0.7 11.1 ± 0.4 11.3 ± 0.3 10.6 ± 0.2 NS 
P (mg/dL) 10.8 ± 1.0a 11.0 ± 0.9a 11.1 ± 0.8a 10.9 ± 0.8a 11.3 ± 1.1a 10.9 ± 0.7a 8.1 ± 0.5b <.0001 
Mg (mEq/L) 1.9 ± 0.3 1.9 ± 0.3 1.9 ± 0.2 1.9 ± 0.3 2.0 ± 0.4 2.0 ± 0.2 1.9 ± 0.2 NS 
Fe (μg/dL) 22 ± 8b 25 ± 9b 18 ± 2b 24 ± 6b 23 ± 4b 41 ± 50b 90 ± 40a <.0001 
TIBC (μg/dL) 814 ± 57a 764 ± 67a 818 ± 86a 803 ± 77a 771 ± 59a 800 ± 100a 397 ± 50b <.0001 
Saturation (%) 3 ± 1b 4 ± 1b 2 ± 0b 3 ± 1b 3 ± 1b 6 ± 7b 23 ± 10a <.0001 
Albumin (g/dL) 4.1 ± 0.2ab 4.1 ± 0.2ab 4.0 ± 0.3b 4.1 ± 0.3ab 4.0 ± 0.2ab 4.3 ± 0.2a 3.4 ± 0.3c 0.0002 
Globulin (g/dL) 1.1 ± 0.3a 1.0 ± 0.2c 1.0 ± 0.2abc 1.0 ± 0.2abc 1.0 ± 0.2bc 1.0 ± 0.2a 1.3 ± 0.4abc 0.02 
Albumin:Globulin 4.1 ± 1.2 4.4 ± 1.0 4.2 ± 1.1 4.2 ± 0.6 4.4 ± 0.9 4.3 ± 0.8 2.9 ± 1.0 NS 
1Values (means ± SD) not sharing common superscript are significantly different (P < 0.05); NS, not significant (P > 
0.05). 
 
2Reference ranges for nursery piglets have been previously reported (25,26). 
 
3BUN, blood urea nitrogen; TIBC, total iron binding capacity.
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Table 1.4. Summary of immune status measurements in piglets fed varying levels of ARA and DHA1
Diet a1 a2 a3-d3 a4 d2 d1 MR P 
ARA/DHA 
(% FA/FA) 0.1/1.0 0.53/1.0 0.69/1.0 1.06/1.0 0.67/0.62 0.66/0.33 0.74/0.01   
M. hyopenmoniae 
(sample/positive) 0.1 ± 0.1 0 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.3 NS 
IgG (μg/ml) 4866 ± 935 4439 ± 967 4293 ± 1018 4952 ± 933 4158 ± 781 4865 ± 942 5903 ± 1031 NS 
IgM (μg/ml) 540 ± 254 470 ± 186 551 ± 257 525 ± 161 534 ± 216 481 ± 176 768 ± 186 NS 
IgA (μg/ml) 160 ± 71b 167 ± 95b 168 ± 63b 157 ± 70b 164 ± 69b 132 ± 56b 408 ± 99a 0.0008 
hsCRP (μg/ml)                       
    Day 3 16.4 ± 10 17 ± 10.3 20.1 ± 10.6 12.5 ± 6.2 10.6 ± 7 11.1 ± 5.9 17.7 ± 9.4 NS 
    Day 7 10.5 ± 2.5 10 ± 3.4 11 ± 6 11.3 ± 3.4 8.8 ± 3.4 8.9 ± 1.6 10.6 ± 2.7 NS 
    Day 14 9 ± 3.3 11.3 ± 4.8 10.4 ± 3.5 9 ± 3.7 6.6 ± 2.8 10.6 ± 1.8 12.5 ± 2.5 NS 
    Day 21 14.4 ± 6.8 16.2 ± 11.9 12.7 ± 4.5 13.1 ± 3 10.2 ± 5.1 14.8 ± 4.3 13 ± 2.6 NS 
    Day 28 13.5 ± 6 13 ± 4.6 14.6 ± 6.2 12.4 ± 3.4 10.6 ± 5.3 15.8 ± 6.8 15.2 ± 4.6 NS 
SAA (μg/ml)                       
    Day 3 23.4 ± 64.4 19.5 ± 29.2 38.6 ± 56.4 26.1 ± 47.9 5.3 ± 14.4 1.6 ± 2.5 17.7 ± 49.3 NS 
    Day 7 17 ± 29.0a 9.5 ± 7.3b 21.1 ± 20.4ab 15.5 ± 23.0b 6.8 ± 4.6b 10.2 ± 9.9b 6.4 ± 7.1b 0.03 
    Day 28 2.5 ± 3.8 2.8 ± 3.8 5.7 ± 5.1 1.9 ± 1 2 ± 1.9 3 ± 4 0.9 ± 0.4 NS 
Hp(µg/ml) 807 ± 818a 235 ± 176b 1137 ± 874ab 355 ± 516b 593 ± 1033ab 812 ± 706a n/a2 0.02 
 
1Hp, haptoglobin; hsCRP, highly-sensitive C-reactive protein; SAA, serum amyloid A. 
 
2Values below limit of detection. 
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of age, with the a1 (low ARA) group having significantly higher levels than 
most other groups.  SAA levels, however, were unaffected by diet on day 3 
and 28 of age.  Likewise, there were minor, statistically significant differences 
in serum Hp levels among FR groups on day 28, although no discernable 
pattern among diets was apparent.  Hp in the MR piglets was below detectable 
limits.  Serum hsCRP levels were similar among all groups on days 3, 7, 14, 
21 and 28 of age.   
 
Discussion 
Human breast milk is considered the gold standard of nutrition for the 
developing infant.  There is broad consensus that human milk composition 
serves as a model for infant formula.  All breast milks naturally contain ARA 
and DHA but the range of reported concentrations is wide and thus studies of 
optimal levels within the natural range are relevant to setting composition 
guidelines.  With interest in optimizing the formula content of ARA and DHA for 
proper development of the infant central nervous and immune systems, it is 
critical to determine the interaction between these two LCPUFA and their 
resulting effect on growth and development.  The present study was carried 
out to determine if there were any safety concerns associated with the dietary 
ARA level on growth, clinical chemistry and immune function in domestic 
piglets when DHA is constant and near the high end of human breast milk 
levels.     
Human term and preterm infants are capable of synthesizing ARA and 
DHA from the dietary precursors linoleic acid (18:2n-6) and linolenic acid 
(18:3n-3), respectively, although rates of endogenous biosynthesis and tissue 
accretion are insufficient to support optimal neural and visual development in 
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western countries in which studies have been conducted (27).  Formulas 
supplemented with single-cell triglyceride oils serve as highly bioavailable 
sources of LCPUFA and enhance plasma and red blood cell content of ARA 
and DHA compared with infants consuming LCPUFA-free formula, and within 
the range of breast-fed infants (28).  However, plasma and red blood cell ARA 
levels serve as surrogate biomarkers for tissue status, especially with regard 
to neural tissue (29).  Functional outcomes, including those associated with 
safety, are thus necessary to develop a complete picture of their effects.   
Growth is considered one of the most useful clinical markers of infant 
development, and over the last two decades, growth outcomes have been 
intimately linked as a basis for addition of ARA to infant formula.  Early studies 
showed a correlation between blood ARA and growth in preterm infants fed 
formula (30), and prompted investigation of the hypothesis that plasma ARA 
levels are crucial to growth outcomes (31).  Recent studies, however, indicate 
that LCPUFA supplementation has a negligible effect on growth (32,33).  In 
the present study, piglets fed 0.1% ARA had marginally lower, but statistically 
significant different body weights on day 7 of age compared with all other FR 
and MR piglets.  These differences in body weight were abolished by day 14 
of age and the 0.1% ARA piglets grew as well as all other FR pigs for the 
remainder of the study.  For all piglets, the rapid rates of growth and 
concomitant demand for nutrients may have exacerbated the requirement for 
ARA during the first two weeks of life.  The approximately eight-fold greater 
growth rate of piglets compared to human infants would be expected to 
amplify effects of ARA on growth, if any (34).  Thus, results from the present 
study are consistent with recent reports in human infants and suggest a 
negligible effect of ARA level on growth. 
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M. hyopneumoniae titers did not differ among any of the dietary 
treatment groups.  Titers were also relatively low compared to the 
manufacturer’s data on RespiSure-One (23).  The HerdChekTM ELISA kit is 
intended to monitor pig herds for outbreaks of M. hyopneumoniae and focuses 
on dividing sample titers into positive versus negative cases relative to a single 
positive control sample, and may have limited ability to detect subtle changes.  
Future studies using this system may benefit from different immunizations or 
immunization schedules to induce higher serum titers and a detection test with 
a broader dose-response curve. 
MR piglets had significantly higher levels of serum IgA than the other 
dietary treatment groups.  One possible explanation is that some or all of the 
IgA is maternally derived.  However, by 24-36 hours after birth, piglets no 
longer transport milk immunoglobulins from the gut into circulation (35).  And, 
based on 125I labeled immunoglobulin clearance rates (36), the average half-
life of maternally-derived IgA is 2.7 days.  Thus, the elevated IgA in the serum 
of MR controls is unlikely to be of maternal origin and may reflect differences 
in the rate of maturation.  Both serum IgG and IgM showed groupwise 
comparison trends similar to IgA but failed to reach significance.  The lack of 
significant differences among the FR groups indicates altering the dietary 
amounts or ratios of ARA to DHA has no adverse effect on immunological 
maturation.  Serum IgG levels, in the present study, were marginally lower 
than previously reported values for sow-fed piglets (37,38) but consistent with 
other formula-fed piglets (37).  Serum IgM levels were comparable to previous 
studies (37,38). 
Serum acute phase protein levels showed few significant differences 
among dietary treatment groups.  Values were highly variable, especially for 
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Hp and SAA, had inconsistent patterns of between-group differences and, in 
some cases, tended to be either higher or lower than previously published 
data (39,40).  The lack of detectable Hp and low concentrations of SAA in the 
MR pigs are inconsistent with previous studies of early life acute phase protein 
concentrations in piglets.  For example, in (39), , SAA levels were slightly 
higher than values for our MR pigs, but showed a similar trend of decreasing 
levels with age.  Where significant differences did exist among dietary 
treatment groups, e.g. day 28 Hp and day 7 SAA, they were not associated 
with higher concentrations of ARA relative to DHA.  Thus, with a battery of 
three acute phase protein tests, we could not find evidence that increasing 
ARA relative to DHA produces a detectable pro-inflammatory state in the 
piglets. 
We have previously examined the safety of ARA and DHA for use in 
formula at 0, 1, 3 and 5 times the levels currently used in conventional infant 
formulas (7).  For the 5x diet, levels of ARA and DHA corresponded to 3.15 
and 1.66% of total FA, respectively, and across the full range of ARA and DHA 
intakes tested, no toxicological effects were observed for growth, clinical 
chemistry or liver histopathology.  Others have observed a similar negligible 
effect on growth outcomes when ARA and DHA were fed 3x the level in 
conventional formulas (8).  Safety concerns associated with providing ARA 
and DHA at different ratios, particularly with regard to growth and immune 
status, led us to conduct the present study.  Here, we observed negligible 
differences among all the FR groups, indicating that the dietary ARA level, 
when DHA is constant at 1.0% of total FA, does not influence functional 
outcomes associated with ARA during the neonatal period.  One possible 
explanation for a lack of difference is that fact that the dietary content of 
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linoleic acid (18:2n-6), roughly 17% of total FA and at a ratio of 11.5:1 with 
linolenic acid (18:3n-3), supported the endogenous biosynthesis of ARA at 
levels sufficient for normal growth and immune function.   
A superficially striking observation from the present study was the large 
difference in growth, hemogram and clinical chemistry parameters between 
the MR and FR piglets.  These results were not unexpected, however, as the 
diet and rearing environment differed tremendously between the two groups.  
In terms of growth, we opted to set intakes for the FR piglets at 80% ad libitum 
intake based on reports of growth patterns for MR piglets (19) and data from a 
pilot study.  This would enable a moderately faster rate of growth for the FR 
piglets, which was observed with a 2 kg difference in body weight between FR 
and MR piglets on day 28 of age.   
Remarkably, absolute brain weights were unaffected by diet.  However, 
relative brain weights expressed as brain weight as a percentage of body 
weight were greatest for the MR piglets, and driven entirely by the larger 
carcasses of the FR groups.  Here, excess nutrients beyond those required for 
brain growth were partitioned to the FR carcass, highlighting the brain’s 
protected growth during the perinatal period.  Differences between MR piglets 
and the FR groups were also observed for biomarkers of blood iron status, 
including hemoglobin, serum iron, total iron binding capacity and percent 
saturation.  Furugouri (41) demonstrated that rapidly growing piglets exhibit 
high levels of erythropoesis and have a heightened daily requirement for 
available iron.  In the present study, the faster rates of growth observed for the 
FR piglets, compared with the MR group, corresponded to an elevated 
demand for iron that was apparently unmet and manifested as poorer blood 
iron status. 
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Current FDA GRAS Notices indicate that ARA be included in infant 
formula at levels at least equal to DHA (42,43), confirmed recently by 
recommendations of an expert panel (44).  Panel recommendations also 
suggest that the formula content of DHA not exceed 0.5% of total FA due to a 
lack of evidence showing further benefit beyond the 0.3% level.  Data from the 
present study show no toxicological effects of DHA when supplemented up to 
1% of total FA, and extend the current body of literature to show that 
comparable levels of ARA are not required to match high DHA to support 
normal growth and immune function.  In Chapter Two, we examine the 
influence of dietary ARA level on tissue ARA and DHA accretion.  It would be 
of further interest to determine the competition between these LCPUFA at the 
tissue level and to determine if dietary ARA level influences functional 
outcomes associated with DHA, such as visual acuity or cognition. 
In conclusion, milk replacer formulas supplemented with varying levels 
of ARA and DHA equally supported normal growth, development and immune 
function of rapidly growing domestic piglets up to 28 days of age.  Dietary ARA 
level, comprising 0.1 – 1.0% of total FA, and fed concomitantly with 1.0% DHA 
produced no toxicological effects on any hemogram, clinical chemistry or 
immune function parameters.  The lack of adverse or toxicological effects in 
piglets consuming the low ARA diet (0.10% total FA) may be due to adequate 
endogenous biosynthesis of ARA from 18:2n-6. 
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CHAPTER TWO 
 
HEART ARACHIDONIC ACID (ARA) IS UNIQUELY SENSITIVE TO DIETARY 
ARA AND DOCOSAHEXAENOIC ACID (DHA) CONTENT IN DOMESTIC 
PIGLETS* 
 
Abstract 
Arachidonic acid (ARA) and docosahexaenoic acid (DHA) are 
commonly added to infant formula to support neonatal growth and 
development.  Higher levels of these long chain polyunsaturated fatty acids 
(FA) in formula may provide some advantage in visual or cognitive 
performance.  This study determined the sensitivity of heart and brain ARA to 
the dietary ARA level in a dose-response design with constant, high DHA.  On 
d3 of age, formula-reared (FR) pigs were assigned to 1 of 6 milk replacer 
formulas that varied in ARA/DHA as follows (%, FA/FA): (a1) 0.1/1.0; (a2) 
0.53/1.0; (a3-d3) 0.69/1.0; (a4) 1.1/1.0; (d2) 0.67/0.62; (d1) 0.66/0.33.  A 
seventh group was maternal-reared.  On d28 of age, piglets were sacrificed 
and organs harvested.  Higher levels of dietary ARA were associated with 
increased heart and liver ARA, while brain ARA remained unaffected.  Dietary 
ARA had no effect on tissue DHA accretion.  Higher levels of dietary DHA 
resulted in higher DHA in the heart, liver and neural tissue, as well as reduced 
liver ARA.  The heart was particularly sensitive, with pigs in the intermediate 
groups having different ARA values (a2, 18.6 ± 0.7%; a3, 19.4 ± 1.0%) and a 
0.17% increase in dietary ARA resulted in a 0.84% increase in heart ARA.  We 
 
 
*Tyburczy, C., Kothapalli, K. S. D., Park, W. J., Blank, B. S., Bradford, K. L., Zimmer, J.P., 
Butt, C. M., Salem, Jr., N., Brenna, J. T. (2010) J Nutr, submitted. 
27
conclude that the heart has a unique responsiveness to the dietary ARA level.  
Further investigations are warranted to determine the clinical significance of 
heart ARA level in the developing neonate. 
 
Introduction 
Arachidonic acid (20:4n-6; ARA) and docosahexaenoic acid (22:6n-3; 
DHA) are two long chain polyunsaturated fatty acids (LCPUFA) that contribute 
to normal growth and development during the perinatal period.  Both are 
natural components of breast milk and since 2002, these LCPUFA have been 
added to infant formulas in the U.S. at target levels of 0.64% and 0.32% of 
total fatty acids (FA) (1).  Mean worldwide levels of ARA and DHA in breast 
milk average 0.47 ± 0.13% total FA (range: 0.24 – 1.0% FA) and 0.32 ± 0.22% 
FA (range: 0.06 – 1.4% FA), respectively, with individual variability in DHA 
attributed largely to maternal diet (2).  Inevitably, the wide variation in breast 
milk LCPUFA as well as the relative inaccessibility to human infant tissue 
presents a major challenge for optimizing levels of ARA and DHA in formula to 
support neonatal development.  
It is well-established that the addition of ARA and DHA to formula 
enhances blood LCPUFA levels equivalent to those of breastfed infants and 
improves visual acuity and cognitive performance compared with infants fed 
LCPUFA-free formula (3-6).  Functional outcome studies with infants provide 
clear evidence for the addition of DHA at 0.32% FA (7,8), while higher DHA 
levels may offer further benefit for neural development, especially in target 
populations (9-11).  Optimal levels of ARA remain to be determined at any 
DHA intake and are based largely on mean global levels in breast milk (12).  
ARA comprises approximately 10 – 12% total FA in human infant central 
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nervous tissue (cerebral cortex and retina) appears to be influenced to a 
greater extent by postnatal age than dietary ARA supply (13).  Animal models 
suggest a relative resistance of brain and retina ARA to dietary ARA intake, 
possibly as a mechanism for regulating its potent bioactivity (14,15).  ARA 
levels in the heart, liver and blood-borne pools vary with ARA intake and may 
compete with n-3 LCPUFA for tissue incorporation (3,16-23), especially in the 
liver (20,23). 
The sensitivity of heart ARA to dietary ARA content has been reported 
a few times but has not been systematically studied (17-19,21). In pigs (21), 
dietary ARA and DHA were maintained at a constant 2:1 ratio and total levels 
varied up to 5 times the target levels in formula. While liver ARA increased 
with only the highest ARA intakes, heart ARA responded in a direct dose-
response manner to each incremental increase in dietary ARA. Further, heart 
ARA more than doubled with the highest ARA level compared with pigs fed 
LCPUFA-free formula.   
We tested the hypothesis that heart and brain ARA is sensitive to 
dietary ARA in a dose-response design with DHA constant at a high 
physiological level.  We examined four levels of ARA ranging from 0.09 to 
1.0% total FA against a background of 1.0% DHA.  Intermediary levels were 
0.53 and 0.67% total FA, where 0.53% is slightly above the worldwide ARA 
mean in human breastmilk and 0.67% is among the highest values reported.  
A DHA dose-response was also included to determine the influence of dietary 
DHA level on tissue ARA incorporation when ARA levels are comparable to 
those added in conventional formula (0.65% ARA).  A randomized 
maternal-reared (MR) reference group was included for comparison. 
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Materials and methods 
Animals and diets 
All procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Cornell University.  On day 3 of life, 
domestic piglets were matched for weight and gender and assigned to one of 
six milk replacer diets (n = 8 per diet).  Piglets in the formula-reared (FR) 
groups were then transferred to the Large Animal Research and Teaching 
Unit, where they were housed individually in raised metal cages and 
maintained on a 16/8 hr light/dark cycle.  The seventh group was MR and 
remained with the dam at the swine facility for the duration of the study.  Intake 
and growth performance is reported in Chapter One.   
Milk replacer formula consisting of 60% experimental diet (Research 
Diets, Inc., New Brunswick, NJ) and 40% Birthright baby pig milk replacer 
(Ralco Nutrition, Inc., Marshall, MN) was fed to FR piglets on days 3 – 28 of 
age.  The ingredient composition and nutrient analysis of the base 
experimental diet is presented in Table 2.1.  A detailed nutrient composition 
and analysis of the Birthright baby pig milk replacer has been reported 
previously (24).  As fed, the milk replacer formula had a caloric density of 0.7 
kcal/mL and a nutrient composition as follows (% wt/wt): protein 26.7, fat 21.9 
and carbohydrate 38.9.  The FA composition of the milk replacer formulas and 
sow milk (day 14 in lactation) is presented in Table 2.2.  Diets varied in the 
ratio of ARA/DHA as follows (%, FA/FA): (a1) 0.1/1.0; (a2) 0.53/1.0; (a3-d3) 
0.69/1.0; (a4) 1.1/1.0; (d2) 0.67/0.62; (d1) 0.66/0.33 (conventional infant 
formula).  Diets a1 – a4 are a dose-response for ARA against DHA constant at 
1.0%, while Diets d1 – d3 are a dose-response for DHA against ARA constant 
at 0.67%.     
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Sampling 
On day 28 of age, piglets were sacrificed via an intravenous injection of 
Fatal Plus (1 mL/4.54 kg body weight; Vortech Pharmaceuticals, Dearborn, MI, 
USA) followed by exsanguination.  Organs were immediately removed, 
weighed and samples flash frozen in liquid nitrogen within 10 min of cessation 
of heart beat.  Cerebral cortex and cerebellum samples were harvested from 
the left hemisphere of each brain prior to submerging individual hemispheres 
in liquid nitrogen.  Internal brain regions were sampled from partially thawed 
left hemispheres at a later period.  Tissues were stored at -80°C until FA 
analysis.   
 
Lipid analysis 
Fatty acid methyl esters (FAME) were prepared from ~50 mg of tissue 
or dry diet and 50 μL sow milk according to the One-step hydrolysis, extraction 
and methylation procedure (25) with previous modifications (26).  A detailed 
protocol for the One-step procedure is presented in Appendix II.  Retinas, 
which were suspended in physiological saline at necropsy, were first dried 
using a Savant SpeedVac Concentrator (Thermo Fisher Scientific, Waltham, 
MA).  FAME were quantified on a 5890 Series II gas chromatograph 
(Hewlett-Packard, Palo Alto, CA) equipped with a BPX70 fused silica column 
(25 m x 0.22 mm i.d. x 0.25 μm film; SGE Incorportated, Austin, TX).  FAME 
were structurally identified by covalent-adduct chemical ionization mass 
spectrometry on a Saturn 2000 mass spectrometer (Varian, Inc., Walnut 
Creek, CA) (27).  An equal weight FAME mixture was used daily to verify 
response factors. 
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Table 2.1 Nutrient composition and analysis of experimental diets 
Composition Content 
Dietary ingredient, % dry matter  
    Dried skim milk 55.0 
    Oil blend 23.9 
    Calcium sodium caseinate 9.6 
    Vitamin mix1 4.8 
    Mineral mix2 4.8 
    Xanthan gum 1.4 
    Methionine, DL 0.5 
Nutrient analysis, % kcal  
    Protein 24.3 
    Carbohydrate 28.7 
    Fat 47.0 
Caloric density (kcal/g) 4.67 
 
1The mineral mix contained (g/kg): 257.8 sucrose, 615.8 dibasic calcium 
phosphate, 106.7 sodium chloride, 11.8 ferric citrate, 4.0 zinc carbonate, 3.4 
magnesium oxide, 0.4 cupric carbonate, 0.2 manganous carbonate, 0.1 
potassium iodate, 0.01 sodium selenite. 
 
2The vitamin mix contained (g/kg): 910.1 sucrose, 75.0 choline bitartrate, 6.2 
vitamin E acetate (50 g/100 g), 3.4 vitamin A acetate (500,000 IU/g), 1.5 
vitamin D3 (100,000 IU/g), 1.3 vitamin B12 (0.1g/100 g mannitol), 0.9 
pantothenic acid (d, calcium), 0.9 niacin, 0.4 biotin (1 g/100 g), 0.1 riboflavin, 
0.1 thiamine HCl 0.03 menadione sodium bisulfite, 0.01 folic acid, 0.01 
pyridoxine HCl. 
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Table 2.2. FA composition of milk replacer formulas and sow milk1
Diet a1 a2 a3-d3 a4 d2 d1 MR 
ARA/DHA 0.1/1.0 0.53/1.0 0.69/1.0 1.1/1.0 0.67/0.62 0.66/0.33 0.74/0.01 
 FA (% total FA) 
Σ SFA + MUFA 79.86 79.94 79.43 79.18 80.02 80.02 83.94 ± 3.16 
ARA 0.09 0.53 0.69 1.06 0.67 0.66 0.74 ± 0.02 
DHA 1.00 1.02 1.01 1.04 0.62 0.33 0.01 ± 0.01 
Σ n-6 17.50 17.52 17.95 18.15 17.76 18.00 15.21 ± 3.08 
Σ n-3 2.53 2.43 2.49 2.51 2.10 1.86 0.71 ± 0.04 
18:2n-6 17.25 16.83 17.11 16.93 16.90 17.19 12.05 ± 2.98 
18:3n-3 1.53 1.41 1.48 1.47 1.48 1.53 0.57 ± 0.06 
18:2n-6/18:3n-3 11.3 12.0 11.6 11.5 11.4 11.3 21.1 
 
1Milk from two sows taken on day 14 of lactation; MR piglets remained with the sow for the duration of the study. 
 
2SFA, saturated FA; MUFA, monounsaturated FA.
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Statistical analysis 
Values are reported as means ± SD.  Statistical analysis was carried 
out using the Fit Model platform of JMP (2008 SAS Institute, 8.0) to fit mixed 
models and tested the hypothesis that all mean treatment values are not 
equal.  Fixed effects were diet, gender, day 3 of age body weight and the full 
factorial of interactions.  The random effect of litter was included the model.  
Interaction effects were considered significant at P < 0.10 and fixed effects at 
P < 0.05.  For each parameter analyzed, effects not considered significant 
were removed from the final model.  Significance of pairwise comparisons was 
determined using the Student’s t-test.  Linear regression analysis was 
performed to determine the dose-response of tissue LCPUFA to the dietary 
ARA and DHA level. 
 
Results 
LCPUFA accretion in liver and heart  
Table 2.3 presents the FA composition of heart and liver.  A detailed 
composition of these tissues is presented in Appendix I (Tables S1 and S2).  
Heart ARA increased with increasing dietary ARA.  Heart ARA levels were 
higher in the a3 group compared with Diet a2 (P = 0.04) such that a 0.17% 
increase in dietary ARA corresponded to an increase of 0.84% in heart ARA 
between the two treatments.  Mean heart ARA was 40% higher in the a4 
group compared with a2 pigs.  Liver ARA increased with increasing dietary 
ARA, although the greatest increase in liver ARA was observed between Diets 
a1 and a2.   
DHA accretion in the liver reflected dietary intake with a1 – a4 pigs 
having the highest liver levels, d1 and d2 pigs having intermediary levels and 
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MR pigs having the lowest liver DHA (Table 2.3).  Similarly, DHA levels in the 
heart reflected dietary DHA content, with a1 – a4 pigs having the highest, d1 
and d2 pigs having intermediary and MR pigs having the lowest heart DHA 
levels (P < 0.0001), although for Diets a1 – a4, a2 pigs had higher heart DHA 
levels than the a1 and a3 groups (P < 0.05).  MR pigs had a strikingly low 
DHA content (0.75 ± 0.08%) that was 6-fold lower than DHA levels in the a2 
group.   
In both the heart and liver, the sum of 22-carbon HUFA reflected tissue 
DHA content and was lowest in d1 and MR pigs (P < 0.0001; Table 2.3).  
Compared with the d3 group, d1 pigs had lower liver DHA and higher liver 
levels of 22:4n-6, 22:5n-6 and 22:5n-3 (P < 0.001).  In the heart, however, d1 
pigs showed increases in 22:4n-6 and 22:5n-3 compared with d3 pigs (P < 
0.0001), while trace levels of 22:5n-6 were detected in all samples.   
 
LCPUFA accretion in neural tissues 
Tables 2.4 and 2.5 present the FA composition of neural tissue from 
pigs fed varying levels of ARA and DHA from day 3 – 28 of age.  The detailed 
FA composition of each neural tissue is presented in Appendix I (Tables S3 – 
S8).  ARA levels in the cerebral cortex, hippocampus, globus pallidus and 
inferior colliculus were similar across all dietary treatments.  ARA levels in the 
cerebellum were significantly influenced by diet (P = 0.007) but showed no 
distinct pattern associated with ARA or DHA intake.  A1 pigs had the lowest 
retina ARA levels of the FR groups, although differences among the means 
only reached significance for the a4, d1 and d2 groups (P < 0.05).   
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Table 2.3. FA composition of heart and liver from piglets fed varying levels of ARA and DHA from days 3 – 28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2 P 
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01   
Liver FA (% total FA) 
ARA 13.92 ± 1.49d 16.14 ± 0.87c 16.12 ± 1.10bc 16.88 ± 1.50b 17.36 ± 0.63b 17.87 ± 1.46a 17.00 ± 1.36abc <.0001 
22:4n-6 1.08 ± 0.29d 1.15 ± 0.22cd 1.27 ± 0.22c 1.36 ± 0.22bc 1.28 ± 0.20bc 1.50 ± 0.10b 2.27 ± 0.35a <.0001 
22:5n-6 0.03 ± 0.06d 0.06 ± 0.05d 0.04 ± 0.04d 0.06 ± 0.07d 0.20 ± 0.09c 0.37 ± 0.11b 1.89 ± 0.53a <.0001 
20:5n-3 0.61 ± 0.14a 0.42 ± 0.15bc 0.45 ± 0.10b 0.36 ± 0.11cd 0.34 ± 0.05cd 0.31 ± 0.04d 0.18 ± 0.06e <.0001 
22:5n-3 0.94 ± 0.11c 0.91 ± 0.09c 0.94 ± 0.12c 0.94 ± 0.14c 1.01 ± 0.07c 1.11 ± 0.16b 1.35 ± 0.20a <.0001 
DHA 10.77 ± 1.77a 11.43 ± 1.22a 10.49 ± 1.41a 10.45 ± 1.79a 9.65 ± 1.01b 7.52 ± 0.69c 2.37 ± 0.30d <.0001 
∑ 22C HUFA4 12.82 ± 1.86a 13.55 ± 1.26a 12.74 ± 1.44ab 12.81 ± 1.90ab 12.14 ± 1.21b 10.51 ± 0.81c 7.88 ± 1.22d <.0001 
Hear  t                       
ARA 14.76 ± 1.07d 18.57 ± 0.67c 19.41 ± 1.00b 20.90 ± 0.93a 19.98 ± 1.38ab 19.09 ± 1.88bc 20.26 ± 1.20ab <.0001 
22:4n-6 0.63 ± 0.09e 0.71 ± 0.09e 0.71 ± 0.06de 0.82 ± 0.09cd 0.88 ± 0.13bc 0.96 ± 0.12b 1.33 ± 0.13a <.0001 
22:5n-6 0.00 ± 0.01b 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 0.02 ± 0.03b 0.08 ± 0.01a <.0001 
20:5n-3 0.75 ± 0.09a 0.54 ± 0.09b 0.49 ± 0.04b 0.41 ± 0.04c 0.42 ± 0.04c 0.32 ± 0.03d 0.28 ± 0.06d <.0001 
22:5n-3 0.59 ± 0.07d 0.59 ± 0.08d 0.57 ± 0.04d 0.57 ± 0.04d 0.71 ± 0.07c 0.83 ± 0.13b 1.24 ± 0.07a <.0001 
DHA 4.81 ± 0.24b 5.20 ± 0.49a 4.78 ± 0.43b 5.01 ± 0.25ab 4.20 ± 0.64c 3.00 ± 0.50d 0.75 ± 0.08e <.0001 
∑ 22C HUFA 6.04 ± 0.25bc 6.50 ± 0.51a 6.06 ± 0.4abc 6.40 ± 0.23ab 5.78 ± 0.72c 4.81 ± 0.59d 3.40 ± 0.15e <.0001 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05). 
  
2ARA/DHA, dietary content of ARA/DHA (%, FA/FA). 
 
3∑ 22C HUFA = ∑ 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Pigs fed 1.0% DHA had significantly higher DHA levels in the cerebral 
cortex, cerebellum and retina than the d1 and MR groups, while d2 pigs 
showed intermediary levels (P < 0.0001; Tables 2.4 and 2.5).  DHA accretion 
in the hippocampus, globus pallidus and inferior colliculus was greatest for 
pigs fed 1.0% DHA and lowest for the MR group (P < 0.05).  For these tissues, 
DHA levels were 17%, 15% and 3% higher, respectively, in the d3 compared 
with d1 pigs, although differences were not statistically significant.   
The sum of the 22-carbon HUFA, corresponding to the sum of 22:3n-9, 
22:4n-6, 22:5n-6, 22:5n-3 and DHA, was similar across all dietary treatments 
in all neural tissues reported (Tables 2.4 and 2.5).  For these tissues, the 
magnitude of the increase in non-DHA 22-carbon HUFA was greatest for 
22:5n-6.  Differences in the composition of 22-carbon HUFA between Diets d1 
and d3 were significant and apparent, with d1 pigs having higher 22:5n-6 in 
cerebral cortex, cerebellum and retina (P < 0.01), and higher 22:4n-6 in 
cerebellum and retina than d3 pigs (P < 0.001). 
 
Tissue ARA and DHA dose-response to diet 
Figure 2.1 summarizes the linear regression analysis for the tissue ARA 
dose-response to the dietary ARA level (Diets a1 – a4).  ARA levels in the 
heart and liver were highly responsive to the dietary ARA content (P < 
0.0001), whereas ARA levels in the cerebral cortex and retina were not 
esponsive to ARA intake.  Regression analysis for the tissue DHA 
dose-response to dietary DHA content (Diets d1 – d3) is presented in 
Appendix I (Figure S1).  Cerebral cortex, retina, liver and heart DHA levels 
increased with dietary DHA content (P < 0.05).  For heart and liver, however, 
differences were most pronounced between Diets d1 and d3, as increasing the  
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Table 2.4. FA composition of cerebral cortex, retina and cerebellum from piglets fed varying levels of ARA and DHA 
from days 3 – 28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
Cerebral cortex FA (% total FA) 
ARA 11.95 ± 0.29 11.82 ± 0.60 11.80 ± 0.35 12.04 ± 0.63 11.93 ± 0.40 11.77 ± 0.68 12.33 ± 0.00 NS 
22:4n-6 4.03 ± 0.52 4.06 ± 0.16 4.09 ± 0.35 4.21 ± 0.60 4.21 ± 0.32 4.19 ± 0.26 4.81 ± 0.30 NS 
22:5n-6 4.49 ± 0.40c 4.44 ± 0.47c 4.68 ± 0.29c 4.61 ± 0.56c 5.52 ± 0.64b 5.49 ± 0.25b 8.26 ± 0.18a <.0001 
22:5n-3 0.20 ± 0.02c 0.19 ± 0.02c 0.19 ± 0.04c 0.19 ± 0.03c 0.20 ± 0.02c 0.25 ± 0.05b 0.32 ± 0.03a <.0001 
DHA 12.10 ± 0.83a 11.91 ± 0.74ab 11.98 ± 0.69ab 11.90 ± 0.69ab 11.30 ± 0.70b 10.56 ± 0.67c 6.88 ± 0.55d <.0001 
∑ 22C HUFA4 20.82 ± 0.81 20.60 ± 0.61 20.94 ± 1.01 20.91 ± 0.99 21.23 ± 0.88 20.49 ± 0.79 20.27 ± 0.72 NS 
Retina  
ARA 9.48 ± 0.23c 9.70 ± 0.61bc 9.66 ± 0.32bc 9.81 ± 0.31b 9.96 ± 0.37b 9.95 ± 0.25b 10.74 ± 0.50a 0.0004 
22:4n-6 1.66 ± 0.15e 1.72 ± 0.12de 1.77 ± 0.12d 1.81 ± 0.17d 1.98 ± 0.19c 2.13 ± 0.12b 2.98 ± 0.17a <.0001 
22:5n-6 1.48 ± 0.30d 1.48 ± 0.32d 1.45 ± 0.16d 1.55 ± 0.30d 2.03 ± 0.64c 2.29 ± 0.26b 5.24 ± 0.39a <.0001 
22:5n-3 0.64 ± 0.04a 0.60 ± 0.05b 0.63 ± 0.06ab 0.60 ± 0.03b 0.55 ± 0.03c 0.60 ± 0.05b 0.60 ± 0.05abc 0.0001 
DHA 20.42 ± 1.20ab 20.70 ± 0.54a 20.07 ± 1.47ab 20.49 ± 1.31ab 19.50 ± 1.50bc 18.68 ± 0.96c 14.16 ± 1.37d <.0001 
∑ 22C HUFA 24.29 ± 1.34 24.61 ± 0.49 24.03 ± 1.49 24.55 ± 1.48 24.20 ± 1.31 23.81 ± 0.90 23.10 ± 0.98 NS 
Cerebellum  
ARA 10.40 ± 0.30c 10.76 ± 0.26bc 11.03 ± 0.31ab 10.44 ± 0.44c 10.95 ± 0.62ab 10.78 ± 0.43bc 11.48 ± 0.73a 0.007 
22:4n-6 3.29 ± 0.41d 3.23 ± 0.38d 3.39 ± 0.32cd 3.43 ± 0.32cd 3.55 ± 0.19c 3.97 ± 0.25b 4.66 ± 0.31a <.0001 
22:5n-6 2.12 ± 0.26cd 2.19 ± 0.34d 2.18 ± 0.19cd 2.17 ± 0.26d 2.70 ± 0.37bc 3.34 ± 1.09b 4.82 ± 0.23a <.0001 
22:5n-3 0.35 ± 0.06bc 0.31 ± 0.05cd 0.32 ± 0.05cd 0.32 ± 0.05d 0.31 ± 0.02cd 0.36 ± 0.05b 0.47 ± 0.04a <.0001 
DHA 11.29 ± 1.61a 11.08 ± 1.68a 11.29 ± 1.19a 11.19 ± 1.44a 10.37 ± 0.75ab 9.83 ± 0.76b 6.10 ± 0.28c <.0001 
∑ 22C HUFA 17.47 ± 1.79 17.19 ± 2.23 17.56 ± 1.51 17.47 ± 1.54 17.36 ± 0.70 17.88 ± 1.37 16.53 ± 0.30 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05). 
 
2ARA/DHA, dietary content of ARA/DHA (%, FA/FA). 
 
3∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Table 2.5. FA composition of hippocampus, globus pallidus and inferior colliculus from piglets fed varying levels of AA 
and DHA from days 3 – 28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
Hippocampus FA (% total FA) 
ARA 10.40 ± 0.89 10.78 ± 0.93 10.57 ± 1.09 10.61 ± 1.57 11.10 ± 0.97 10.85 ± 1.23 11.77 ± 0.96 NS 
22:4n-6 4.57 ± 0.36 4.68 ± 0.43 4.63 ± 0.57 4.72 ± 0.63 4.78 ± 0.44 5.03 ± 0.51 5.37 ± 0.43 NS 
22:5n-6 2.89 ± 0.22c 2.96 ± 0.39c 3.06 ± 0.39cd 2.68 ± 0.67d 3.71 ± 0.40b 3.31 ± 0.53bc 5.58 ± 0.60a <.0001 
22:5n-3 0.24 ± 0.03ab 0.22 ± 0.05bc 0.22 ± 0.02bc 0.20 ± 0.05bc 0.19 ± 0.02c 0.24 ± 0.04ab 0.27 ± 0.04a 0.009 
DHA 9.89 ± 0.26a 9.74 ± 1.43a 9.66 ± 0.68ab 9.63 ± 1.73a 9.44 ± 1.03a 8.27 ± 1.48b 6.12 ± 0.68c 0.0002 
∑ 22C HUFA4 17.20 ± 1.41 17.60 ± 1.87 17.13 ± 1.99 17.23 ± 2.89 18.12 ± 1.44 16.84 ± 2.23 17.34 ± 0.64 NS 
Globus pallidus  
ARA 10.33 ± 0.68 9.33 ± 1.28 10.07 ± 0.44 9.92 ± 0.76 10.02 ± 0.88 10.09 ± 0.96 10.73 ± 0.82 NS 
22:4n-6 3.81 ± 0.32bc 3.59 ± 0.73b 4.25 ± 0.51ab 3.98 ± 0.87bc 3.72 ± 0.37bc 4.04 ± 0.58bc 4.78 ± 0.65a 0.02 
22:5n-6 2.93 ± 0.37b 2.24 ± 0.77c 2.81 ± 0.40bc 2.64 ± 0.58bc 3.16 ± 0.73b 3.04 ± 0.78b 5.40 ± 0.92a <.0001 
22:5n-3 0.15 ± 0.12 0.12 ± 0.04 0.13 ± 0.03 0.13 ± 0.02 0.11 ± 0.04 0.14 ± 0.06 0.19 ± 0.06 NS 
DHA 9.45 ± 0.97a 8.09 ± 2.61ab 8.80 ± 0.94ab 8.18 ± 1.36ab 7.91 ± 1.95b 7.66 ± 1.68bc 6.08 ± 0.35c 0.01 
∑ 22C HUFA 16.74 ± 1.12 14.49 ± 3.72 16.44 ± 1.37 15.41 ± 2.20 15.37 ± 2.68 15.34 ± 2.50 16.92 ± 1.43 NS 
Inferior colliculus   
ARA 8.58 ± 0.35 8.55 ± 0.75 8.85 ± 0.84 8.61 ± 0.52 8.63 ± 0.50 8.97 ± 0.73 9.45 ± 1.25 NS 
22:4n-6 3.54 ± 0.21b 3.36 ± 0.19b 3.55 ± 0.31b 3.56 ± 0.29b 3.42 ± 0.30b 3.70 ± 0.35b 4.68 ± 1.16a <.0001 
22:5n-6 1.58 ± 0.49bc 1.50 ± 0.35c 1.60 ± 0.45bc 1.62 ± 0.52bc 1.93 ± 0.53b 1.91 ± 0.32b 3.76 ± 0.45a <.0001 
22:5n-3 0.19 ± 0.02ab 0.18 ± 0.04abc 0.19 ± 0.04ab 0.15 ± 0.02c 0.16 ± 0.03bc 0.18 ± 0.03bc 0.21 ± 0.06a 0.02 
DHA 10.71 ± 0.94a 10.32 ± 1.88a 10.84 ± 1.50a 9.58 ± 1.21a 10.18 ± 1.27a 10.53 ± 0.85a 6.27 ± 1.14b <.0001 
∑ 22C HUFA 16.35 ± 1.10 15.66 ± 2.18 16.46 ± 2.03 15.28 ± 1.60 16.02 ± 1.46 16.61 ± 1.23 15.40 ± 1.74 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (%, FA/FA). 
 
3∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA.  
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 DHA content from 0.62 to 1.0% total FA (Diets d2 vs. d3) did not significantly 
increase heart or liver DHA levels.  Cerebellum and hippocampus DHA levels 
also increased with dietary DHA content (P < 0.05), while globus pallidus and 
inferior colliculus DHA levels did not correlate with dietary DHA content (Figure 
S2, Appendix I). 
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Figure 2.1. ARA tissue dose-response to dietary ARA with constant DHA 
(1.0% total FA).  Dietary ARA content for a1, a2, a3 and a4 was 0.09, 0.53, 
0.69 and 1.06% total FA, respectively.  (A) Heart and (b) Liver responded 
significantly (P < 0.0001) while (C) Brain (cerebral cortex) and (D) Retina did 
not.  Each point represents one animal (n = 32 per panel).  P < 0.05 indicates 
significant correlation between dietary ARA content and tissue ARA level; NS, 
not significant.  Student’s t-test used to determine significance of pairwise 
comparisons of mean tissue ARA content; means not sharing a common letter 
are significantly different (P < 0.05). 
 
ARA and DHA competition for tissue incorporation 
Dietary ARA level had no effect on DHA accretion in the heart, liver or 
neural tissues (P > 0.05) (Figure 2.2; Figure S3, Appendix I).  Conversely, 
there was an apparent competition between liver ARA and dietary-derived 
40
DHA (Diets d1 – d3), with d3 pigs showing lower liver ARA levels than d1 pigs 
(P = 0.004) (Figure 2.3).  This competition was not detected in the heart, brain 
or retina, indicating that the dietary DHA content has no effect on ARA levels 
in these tissues (Figure 2.3). 
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Figure 2.2. DHA tissue dose-response to dietary ARA content with constant 
DHA (1.0% total FA).  Dietary ARA content for a1, a2, a3 and a4 was 0.09, 
0.53, 0.69 and 1.06% total FA, respectively.  Increasing ARA had no effect on 
DHA levels in (A) Heart, (B) Liver, (C) Brain (cerebral cortex) or (D) Retina.  
Each point represents one animal (n = 24 per panel). P < 0.05 indicates 
significant correlation between dietary ARA content and tissue DHA level; NS, 
not significant.  Student’s t-test used to determine significance of pairwise 
comparisons of mean tissue DHA content; means not sharing a common letter 
are significantly different (P < 0.05). 
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Figure 2.3. ARA tissue dose-response to dietary DHA content with constant 
ARA (0.67% total FA).  Dietary DHA content for d1, d2 and d3 was 0.32, 0.62 
and 1.01% total FA, respectively.  Increasing DHA reduced ARA levels in (B) 
Liver but not (A) Heart, (C) Brain (cerebral cortex) or (D) Retina.  Each point 
represents one animal (n = 24 per panel).  P < 0.05 indicates significant 
correlation between dietary DHA content and tissue ARA level; NS, not 
significant.  Student’s t-test used to determine significance of pairwise 
comparisons of mean tissue ARA content; means not sharing a common letter 
are significantly different (P < 0.05). 
 
Discussion 
The neonatal pig serves as a practical biomedical model of human 
infant development.  Pigs are similar to humans in their metabolic responses, 
genetics of the FA desaturases and rates of perinatal brain growth (28,29).  
Their rapid postnatal growth enables facile collection of pre-clinically relevant 
data over a relatively short study duration.   
The sensitivity of heart ARA to the dietary ARA has been reported from 
time to time in pigs (19,21) and rats (17,18), yet it is poorly understood on a 
mechanistic basis and its clinical significance is unknown.  In the present 
study, heart ARA levels reflected dietary ARA content and were significantly 
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different for pigs in all ARA groups including those with intermediate intakes, 
a2 (18.6 ± 0.7% total FA) and a3 (19.4 ± 1.0% total FA), indicating that heart 
ARA is limited by intake, at least at high DHA levels.  These observations are 
particularly relevant to ARA recommendations for infant formula as 0.53% (a2) 
is slightly above the worldwide ARA mean in human breast milk and 0.67% 
(a3) is the level currently added in formula and is near the high end of breast 
milk values reported.  ARA serves several known functions in cardiac 
physiology, such as providing precursor for eicosanoid signaling molecules 
and acting directly to modulate voltage-gated ion channel activity and cellular 
excitability (30).  The degree to which heart ARA status influences cardiac 
physiology in the developing neonate, as well as the potential long term 
implications, remains to be determined. 
Biosynthesis of ARA and DHA from the nutritionally essential linoleic 
and linolenic acids occurs through a series of elongation and desaturation 
reactions catalyzed by a common set of enzymes (31).  Studies with humans 
indicate that the rate of postnatal endogenous DHA synthesis is insufficient to 
support DHA accretion in neural tissues (32,33), and results in poorer visual 
and cognitive performance compared with infants consuming preformed DHA 
(3,5,6).  These observations provide the basis for the addition of DHA to 
formula.  Rates of endogenous synthesis of ARA from linoleic acid appear 
sufficient to maintain brain ARA levels in adult rats (34) but remain to be 
thoroughly investigated in growing animals.  In the present study, higher levels 
of dietary ARA correlated with increased heart and liver ARA, while brain ARA 
was constant and unaffected by ARA intake.  The trend for a modest increase 
in retina ARA with increasing dietary ARA was not supported by the linear 
regression analysis for the ARA dose-response.  Liver lipids typically reflect 
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dietary FA content but are also influenced by the expression and regulation of 
enzymes involved in LCPUFA biosynthesis (31,35).  The heart, too, expresses 
the FA desaturases and elongase enzymes (Elovl-1, -5 and -6) capable of 
synthesizing ARA, but is not generally considered a major site of LCPUFA 
biosynthesis (36).  The sensitivity of the heart to dietary ARA level therefore 
suggests that the ARA content is influenced predominantly by preferential FA 
uptake and incorporation.  Further, these data indicate that the rate of 
endogenous ARA biosynthesis may not be sufficient to match ARA accretion 
in the growing the heart.  
The choice to include an MR reference group provided a unique 
opportunity to investigate the contribution of sow milk, essentially devoid of 
DHA but not ARA, to the LCPUFA status of the developing offspring.  This 
treatment is not unlike an extreme case of DHA-deficient breast milk that is 
reflective of few human populations worldwide (2,37).  Because of this, we 
advise caution in extending results observed with the MR group, in particular 
comparing MR pigs with the FR groups fed higher levels of DHA, to 
breastfeeding practices in humans.  
The competition between n-3 and n-6 for tissue incorporation and the 
resulting effect on LCPUFA biosynthesis is well-studied.  The relative 
availability of linoleic and linolenic acids, as well as their LCPUFA derivatives, 
drives the biosynthesis of n-3 and n-6 LCPUFA and modulates tissue levels of 
the two FA families in a reciprocal manner (20,38,39).  Over the range of 
dietary ARA levels in the present study, tissue DHA was constant and 
unaffected by diet.  On the other hand, we observed a specific reduction in 
liver ARA with the highest DHA intakes, consistent with previous reports in 
pigs (19) and baboon neonates (23) consuming preformed DHA.  These 
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observations reinforce the concept that ARA and DHA in the liver are closely 
linked to diet because of the liver’s central role in LCPUFA biosynthesis, and 
are specific to function in the heart and neural tissue; all tissues being 
modulated by genetic and extra-dietary factors. 
The sensitivity of central nervous tissue DHA level has been previously 
investigated in numerous studies with term and preterm neonatal baboons 
(22,23,40).  The brain consistently shows increased region-specific DHA 
accretion related to level and duration of preformed DHA feeding, and 
prematurity appears important.  Here we observed higher levels of DHA in all 
tissues with increasing DHA content.  Pigs in the high DHA group showed 
significantly higher levels of DHA in the cerebral cortex, retina and cerebellum 
compared with pigs in the low DHA group. Increases in mean DHA were 13%, 
7% and 15%, respectively for these neural tissues.  DHA levels in the 
hippocampus, globus pallidus and inferior colliculus were 17%, 15% and 3% 
higher in the high DHA group compared with the low DHA group; while these 
differences were not statistically significant they may be of biological 
importance.  The relative insensitivity of basal ganglia, limbic and midbrain 
regions to postnatal dietary DHA consumption, compared with the cerebral 
cortex, is consistent with Hsieh et al. (23), and suggests that these deep brain 
regions may be influenced to a greater extent by the DHA status of the mother 
during gestation.  Thus, these data support the recent dietary 
recommendations on total fat and fatty acids by the FAO/WHO for the 
provision of 200 mg/day DHA in the diets of pregnant and lactating women 
(41). 
Pigs that exhibited the lowest neural tissue DHA also showed enriched 
tissue 22:4n-6, 22:5n-6 and 22:5n-3, with greatest increases occurring in 
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22:5n-6.  The increase in tissue 22:5n-6 in animals fed n-3-inadequate diets is 
well-characterized (42-44) and presumably occurs as an alternate substrate 
source for DHA-dependent functions in neural tissue.  Recent examination of 
the frontal cortex from rat pups fed an n-3-deficient diet revealed a highly 
specific substitution of 22:5n-6, but not 22:4n-6 or ARA for DHA in brain 
phosphatidyl ethanolamine and phosphatidyl serine (45).  Tight regulation of 
the “reciprocal replacement” of DHA and 22:5n-6 (42) among brain 
phospholipid molecular species illustrates the essential structure-function 
relationship between DHA and outcomes such as vision or cognition.  
Functionally, low DHA levels in neural tissue cannot be fully compensated by 
increased 22:5n-6 and manifests as poorer electroretinogram performance 
(46) and spatial learning (47).  In the present study, the composition difference 
in neural tissue 22-carbon HUFA between diets d1 and d3 is of particular 
interest.  Pigs in the low DHA group had significantly lower DHA and higher 
22:5n-6 in cerebral cortex, cerebellum and retina.  DHA at 0.32% total FA is 
the level currently added to infant formulas.  Higher levels may provide further 
benefit for visual acuity and cognition, especially in target populations with 
endogenously low DHA status (5,9,11).  Importantly, the d1-d3 groups held 
ARA at 0.67% which is at the highest levels found in human breast milk (2), 
and similar to the MR group which had extremely low DHA (Table 2.2). 
Changes in tissue FA composition could influence markers of formula 
safety and measures of overall development.  The dietary ARA level (0.09 – 
1.0% total FA) had a negligible effect on safety as assessed by clinical 
chemistry and measures of immune function in our piglets fed 1.0% DHA 
(Chapter One).  Likewise, there were no differences in growth among them, 
and no reported differences in vigor by those observing piglets daily.    
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In summary, results from the present study demonstrate a 
tissue-specific responsiveness to the dietary ARA level in rapidly growing 
neonatal pigs.  Whereas brain ARA remained unaffected by diet ARA, heart 
and liver ARA levels were responsive.  Dietary ARA level had no effect on 
DHA accretion in heart, liver or neural tissue.  The magnification of heart ARA 
levels with increasing dietary ARA content suggests that the growing heart 
specifically incorporates and concentrates ARA at a rate that may exceed the 
biosynthetic capacity for ARA.  Further investigations are warranted to 
determine the biological implication of heart ARA status in the developing 
neonate. 
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CHAPTER THREE 
 
EVALUATION OF BIOEQUIVALENCY AND TOXICOLOGICAL EFFECTS OF 
THREE SOURCES OF ARACHIDONIC ACID (ARA) IN DOMESTIC 
PIGLETS* 
 
Abstract 
 Arachidonic acid (ARA) is routinely added to infant formula to support 
growth and development.  We evaluated the safety and bioequivalence of 
three oils providing ARA for potential use in infant formula using the neonatal 
pig model.  On d 3 of age, domestic pigs were matched for weight and gender 
and assigned to 1 of 3 formula diets, each containing ARA at 0.62 – 0.67% 
total fatty acids.  Long chain polyunsaturated fatty acids (LCPUFA) in the 
Control diet were provided by ARASCO and DHASCO (Martek Biosciences, 
Corp.) in a formulation similar to Enfamil; ARA in experimental diets (a1 and 
a2) came from proprietary blends of oils.  Blood collection was performed 
weekly and body weight measurements taken every 2-3 d.  Pigs were 
sacrificed on d 22 and organs sampled.  Intake and growth was similar across 
all diets.  Few differences in clinical chemistry and hemogram parameters 
were detected, with aspartate aminotransferase and creatine kinase levels 
highest in the Control.  Liver sections had no signs of histopathological 
abnormality.  ARA and docosahexaenoic acid (DHA) levels in cerebral cortex, 
retina and heart were not different across all diets.  In the liver, ARA levels  
 
 
*Tyburczy, C., Brenna, M. E., Kothapalli, K. S. D., Blank, B. S., Valentine, H., 
McDonough, S. P., Banavara, D., Diersen-Schade, D. A., Brenna, J. T. (2010) 
Food Chem Toxicol, submitted. 
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were 2% lower in a1 pigs compared with the Controls (P = 0.002) while DHA 
levels in the a1 pigs averaged 7% higher than the Control and a2 groups (P < 
0.05).  We conclude that the experimental ARA oils are safe and bioequivalent 
to a commercially available ARA source in the domestic piglet.  
 
Introduction 
 Arachidonic acid (ARA) is a long chain polyunsaturated fatty acid 
(LCPUFA) that is routinely added to infant formula along with 
docosahexaenoic acid (DHA).  Both are natural components of breast milk and 
are important for growth and development during the perinatal period (1-3).  
ARA and DHA serve as the major LCPUFA in central nervous tissue and in 
the heart ARA comprises upwards of 25% of total fatty acids (FA) (Chapter 
Two).  Tissue ARA and DHA accretion during growth occurs via the uptake of 
preformed LCPUFA from breast milk or formula or through the endogenous 
biosynthesis of LCPUFA from the dietary essential FA, linoleic and linolenic 
acids.  Rates of endogenous ARA and DHA biosynthesis appear to be a 
limiting factor in the accretion of LCPUFA in tissues  (4-6)(Chapter Two), 
indicating a requirement for these LCPUFA in the diets of human infants.  In 
1994, the FAO/WHO set recommendations for ARA and DHA in the formula of 
term infants at 0.66% and 0.33% of total FA, respectively (7).  These levels 
are based largely on mean worldwide breast milk levels (8,9) and supported 
by the evidence for benefit in vision and cognitive performance in clinical 
studies with human infants (10,11).  
 Single-cell oils serve as a convenient vehicle for adding target levels of 
LCPUFA to commercial infant formula.  In the U.S., two main sources of ARA 
have been determined to be Generally Regarded as Safe (GRAS) for use in 
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infant formula, ARASCO (Martek Biosciences, Corp., Columbia, MD) (12,13) 
and SUNTGA40S (Suntory, Ltd., Osaka, Japan) (14).  Both are triglyceride oils 
derived from the fungus Mortierella alpina (M. alpina) and contain ARA at 
approximately 40% total FA.  A third oil, “refined arachidonic acid-rich oil” 
(RAO; Cargill, Inc., Wuhan, China) also derived from M. alpina is currently 
pending FDA approval for use in preterm and term infant formulas (15).  These 
ARA oils may be derived from a common fungal source but differences in the 
manufacturing process inevitably lead to subtle variations in the final product.  
Of particular importance here are the levels of trace chemical and fat soluble 
components, and potentially bioactive microbiological constituents.  While an 
ARA oil may comprise less than 2% of the total fat in formula, the extended 
consumption of these oils by the vulnerable, growing infant population may 
exaggerate any toxicological or allergenic effect caused by trace or undetected 
contaminants (16,17).  Thus, preclinical feeding studies with animals are 
essential to determine the safety of novel formulations for use in the diets of 
human infants.    
 The present study sought to determine the safety and bioequivalence of 
two experimental, proprietary ARA oils for potential use in infant formula 
compared with the commercially available ARASCO using the neonatal pig 
model.  Piglets were fed one of three ready-to-use formulas that provided ARA 
at 0.64% and DHA at 0.34% of total FA from day 3 to 22 of life, upon which 
tissues were analyzed for ARA and DHA accretion and livers examined for 
pathohistological changes.  We hypothesized that the experimental ARA oils 
would be safe, nutritionally bioequivalent to ARASCO and produce no 
toxicological effects in our neonatal pigs. 
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Materials and methods 
Animals 
 All procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Cornell University.  Domestic piglets were 
selected for gender and weight from 5 sows at the swine facility at Cornell 
University.  One day before the scheduled, term farrowing date, pregnant 
sows were injected with 2 cc of Lutalyse (Pfizer Animal Health, Kalamazoo, 
MI) to induce farrowing and obtain a block of piglets with the same birth date.  
Newborn piglets were processed according to standard facility practices (i.e. 
intramuscular injection of iron dextran (100 mg) and penicillin G (½ cc), tooth 
clip, tail dock, ear notch) and remained with the sow until day 3 of age, upon 
which they were matched for weight and assigned to one of three 
experimental formula diets (n=8 per diet).  Piglets were then transported to the 
campus large animal research facility where they were housed individually in 
raised metal cages, provided appropriate enrichment and maintained on a 
16/8 hr light/dark cycle. 
 
Diets 
 Experimental formulas were designed to meet or exceed nutrient 
requirements for growing pigs 3 – 5 kg in body weight (18).  Milk replacer diets 
were prepared as ready-to-use formulas that provided 1.0 kcal/ml with a target 
nutrient composition as follows (% wt/wt): protein, 4.9; fat, 5.5; ash, 1.2.  The 
detailed composition and nutrient analysis for the experimental formulas is 
presented in Table 3.1.  Target specifications for ARA and DHA were 35.8 and 
17.9 mg/100 kcal.  LCPUFA in the Control diet were supplied by ARASCO and 
DHASCO (Martek Biosciences, Corp., Columbia, MD) in a formulation similar  
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Table 3.1. Nutrient composition of experimental diets 
Nutrient (% wt/wt)1 Control a1 a2 
    Fat 5.5 5.6 5.6 
    Protein 4.9 4.9 4.8 
    Carbohydrate 6.4 6.1 6.2 
    Ash 1.2 1.2 1.2 
    Total solids 18.1 17.7 17.8 
Mineral (mg/100 kcal)    
    Na 59.3 62.6 60.6 
    Mg 15.0 14.5 14.6 
    P 146.0 149.7 146.3 
    K 306.3 301.9 304.4 
    Ca 217.5 214.8 208.8 
Vitamin (units/100 kcal)    
    Vitamin E (IU) 1.6 1.6 1.6 
    Vitamin K (mcg) 16.7 18.3 17.5 
    Vitamin D (IU) 13.4 13.2 13.5 
    Vitamin C (mg) 6.3 6.7 6.3 
    Vitamin A (IU) 83.0 88.0 83.0 
    Thiamine HCl (mcg) 82.8 67.1 66.8 
    Riboflavin (mcg) 204.5 185.7 188.3 
    Vitamin B6 (mcg) 65.6 60.5 69.4 
    Vitamin B12 (mcg) 0.5 0.4 0.5 
 
1Composition taken as percent of total weight (wt). 
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Table 3.2. FA composition of experimental diets1
Diet Control a1 a2 
 FA (% total FA) 
10:0 0.70 ± 0.02 0.74 ± 0.02 0.46 ± 0.01 
12:0 8.19 ± 0.08 8.12 ± 0.09 7.37 ± 0.07 
14:0 4.21 ± 0.04 4.24 ± 0.03 4.20 ± 0.03 
16:0 21.76 ± 0.05 21.77 ± 0.08 22.07 ± 0.09 
16:1 0.18 ± 0.01 0.18 ± 0.01 0.19 ± 0.02 
18:0 4.58 ± 0.02 4.50 ± 0.02 4.53 ± 0.04 
18:1 38.14 ± 0.12 37.96 ± 0.15 38.59 ± 0.15 
18:2n-6 17.74 ± 0.03 17.86 ± 0.06 17.96 ± 0.04 
Conjugated 18:2 0.29 ± 0.03 0.31 ± 0.01 0.25 ± 0.03 
18:3n-6 0.10 ± 0.01 0.11 ± 0.00 0.10 ± 0.01 
18:3n-3 2.00 ± 0.03 2.01 ± 0.04 2.01 ± 0.03 
20:0 0.35 ± 0.01 0.35 ± 0.00 0.36 ± 0.00 
20:1 0.21 ± 0.01 0.21 ± 0.01 0.21 ± 0.01 
20:2n-6 0.03 ± 0.00 0.01 ± 0.01 0.03 ± 0.00 
20:3n-6 0.07 ± 0.00 0.08 ± 0.01 0.08 ± 0.00 
ARA 0.67 ± 0.01 0.62 ± 0.00 0.67 ± 0.00 
22:0 0.27 ± 0.01 0.30 ± 0.01 0.32 ± 0.01 
DHA 0.35 ± 0.01 0.35 ± 0.01 0.34 ± 0.01 
23:0 0.04 ± 0.01 0.05 ± 0.01 0.05 ± 0.00 
24:0 0.12 ± 0.00 0.21 ± 0.01 0.22 ± 0.01 
∑ SFA2 40.18 ± 0.15 40.22 ± 0.20 39.53 ± 0.17 
∑ MUFA 38.53 ± 0.13 38.36 ± 0.15 38.99 ± 0.14 
∑ n-6 18.62 ± 0.03 18.67 ± 0.06 18.83 ± 0.04 
∑ n-3 2.34 ± 0.04 2.36 ± 0.03 2.35 ± 0.04 
18:2n-6/18:3n-3 8.89 ± 0.15 8.91 ± 0.18 8.94 ± 0.16 
 
1Values represent means ± SD, n = 3 extractions per diet. 
 
2SFA, saturated FA; MUFA, monounsaturated FA. 
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to that currently used in the commercial human infant formula Enfamil (Mead-
Johnson Nutrition, Evansville, IN).  LCPUFA in the experimental diets, a1 and 
a2 were provided by a proprietary blend of oils that may include SUNTGA40S, 
RAO or a novel ARA source.  The detailed FA composition of the experimental 
formulas is presented in Table 3.2.  Fresh formula was provided three times 
per day in stainless steel bowls fixed into the cage doors and water was 
offered ad libitum.  Piglets were fed at 80% ad libitum intake, based on pilot 
data, and formula intakes were recorded daily. 
 
Sampling 
 Body weights measurements were taken every other day during the first 
week of life and thereon every third day for the remainder of the study.  Non-
fasted blood samples were collected from the anterior vena cava into 
EDTA-containing vacutainer tubes (BD, Franklin Lakes, NJ) on days 3, 7, 14 
and 21 of age.  Whole blood was separated into plasma, red blood cell (RBC) 
and white cell fractions using Leucosep tubes (Grenier Bio-One, Monroe, NC) 
with lymphocyte separation media (Mediatech, Inc., Manassas, VA) according 
to manufacturer’s directions.  Piglets were sacrificed on day 22 of age via an 
intravenous injection of Fatal Plus (1 ml/4.54 kg body weight; Vortech 
Pharmaceuticals, Dearborn, MI, USA) followed by exsanguination.  Organs 
were harvested, weighed and samples flash frozen in liquid nitrogen within 10 
minutes of cessation of heart beat. 
 
Clinical chemistry and hemogram analysis 
 Plasma and EDTA-blood from piglets on day 21 of age were delivered 
promptly to the Animal Health Diagnostic Center (College of Veterinary 
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Medicine, Cornell University) for analysis of clinical chemistry and hemogram 
parameters.  
 
Liver histopathology 
 Freshly harvested samples from the right central lobe (~ 1 g) were fixed 
in 10% neutral buffered formalin and submitted to the Pathohistology 
Laboratory (College of Veterinary Medicine, Cornell University) where they 
were embedded in wax, sectioned and stained with hematoxylin and eosin.  
Sections were examined under light microscope by a veterinary pathologist for 
determination of histopathological abnormalities. 
 
Fatty acid analysis 
 FA methyl esters (FAME) were prepared from approximately 50 mg 
tissue and 50 μl of plasma, RBC and formula according to the One-step 
hydrolysis, extraction and methylation procedure (19) with modifications (20).  
A detailed protocol for the One-step method is presented in Appendix II.  
Retinas, which were suspended in saline at necropsy, were first dried using a 
Savant SpeedVac Concentrator (Thermo Fisher Scientific, Waltham, MA).  
FAME were quantified on a 5890 Series II gas chromatograph 
(Hewlett-Packard, Palo Alto, CA) equipped with a BPX70 fused silica column 
(25 m x 0.22 mm i.d. x 0.25 μm film; SGE Incorportated, Austin, TX) and 
integrated using PeakSimple 3.78 software (SRI Instruments, Torrance, CA).  
An equal weight FAME mixture was used daily to verify response factors.  
FAME were structurally identified by covalent-adduct chemical ionization mass 
spectrometry on a Saturn 2000 mass spectrometer (Varian, Inc., Walnut 
Creek, CA) attached to a Varian Star 3400 gas chromatograph (21). 
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Statistical analysis 
 Statistical analysis was carried out using the Fit Model platform of JMP 
(2008 SAS Institute, 8.0) to fit mixed models.  Fixed effects were diet, gender, 
day 3 of age body weight and the full factorial of interactions.  Interaction 
effects were considered significant at P < 0.10 and fixed effects at P < 0.05.  
For each parameter analyzed, effects not considered significant were removed 
from the final model.  Random effects were litter and animal nested within litter 
for repeated measures of body weight and RBC FA content.  Significance of 
pairwise comparisons was determined using the Student’s t-test.  Values are 
reported as means ± SD.  Linear regression analysis was performed to 
determine the relationship between RBC LCPUFA content and postnatal age. 
 
Results 
Formula composition 
 Total formula intakes averaged 29.6 ± 1.7 L and were similar for all 
three dietary treatment groups.  The experimental formulas provided 1 kcal/ml, 
corresponding to a mean total energy intake of 29,600 ± 1,700 kcal per pig 
and a mean daily intake of 1.5 L or 1,500 kcal.  Mean total intake of ARA was 
10.60 ± 0.59 g, while the mean total intake of DHA was 5.30 ± 0.30 g.   
 
Clinical observations and growth 
 All 24 piglets remained on the study until day 21 of age, and very few 
health ailments were noted during the course of the study.  Loose stools 
during the first week of life were the greatest concern, although by the second 
week of life, the occurrence of loose stools had cleared in most piglets.  One 
piglet was given an intramuscular injection of penicillin G benzathine (75,000 
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IU) by the attending veterinarian on day 11 of age for an undiagnosed, yet 
persistent disinterest in consuming formula.  That animal grew significantly 
less than all other pigs starting on day 13 of age, as determined using Grubb’s 
test for statistical outliers, and was removed from the body weight analysis 
starting at this time point.   
 The temporal pattern of body weight gain during the study is presented 
in Figure 3.1.  Piglets weighed 2.1 ± 0.2 kg at the start of the study (day 3 of 
age) and rapidly grew to 8.4 ± 0.4 kg by day 22 of age.  Mean body weights 
were similar among the three dietary treatments at every time point measured.  
Organ weights at necropsy, both relative and absolute, were similar among all 
dietary treatment groups.  Figure 3.2 presents the summary of relative organ 
weights (organ weight as a percentage of body weight at necropsy) for piglets 
sacrificed on day 22 of age. 
 
Hemogram and clinical chemistry 
 A summary of mean hemogram and clinical chemistry parameters is 
presented in Table 3.3.  Only two parameters, aspartate aminotransferase 
(AST) and creatine kinase, were determined to be significantly influenced by 
diet.  Control pigs had significantly higher AST (37 ± 13 U/L) than a1 (28 ± 7 
U/L) and a2 (25 ± 7 U/L) pigs (P = 0.01), and higher creatine kinase (895 ± 
520 U/L) than the a1 (541 ± 227 U/L) and a2 (520 ± 228 U/L) pigs (P = 0.001).  
AST and creatine kinase levels were similar between the a1 and a2 groups.  
Additional parameters that were unaffected by diet were mean cell volume, 
mean cell hemoglobin, mean cell hemoglobin concentration, red cell 
distribution width, segmented neutrophils, monocytes, eosinophils, basophils, 
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large unstained cells, mean platelet volume, creatinine, phosphate and total 
bilirubin (data not presented). 
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Figure 3.1. Temporal pattern of body weight gain in piglets from day 3 to 22 of 
age.  Values represent means ± SD, n = 8/diet.  One piglet from Diet a1 was 
not included in body weight measurements on days 13 – 22 due to a slower 
rate of growth caused by an undiagnosed, yet persistent disinterest in formula 
consumption.  Body weights were similar among all dietary treatment groups 
at every time point measured. 
 
Liver histopathology 
 Histological diagnosis: Normal.  “Comment: All samples were within 
normal histopathological limits.  The lobular architecture was intact, the portal 
regions were unremarkable and there was no evidence of cholestasis.  
Hepatocytes were uniform in size and shape, replete with glycogen and 
contained no discernable lipid.  No mitrotic figures were observed and only 
rare binucleate hepatocytes were noted.  Occasional Kupffer cells were 
present but no hepatic stellate (Ito) cells could be identified.  Variable numbers 
of small foci of extramedullary hematopoietic tissue were randomly dispersed 
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throughout the parenchyma (incidental).  No histopathological changes were 
present in the sections examined.  In particular, no changes similar to those 
described in rodent studies of peroxisome proliferator exposure were 
detected.” 
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Figure 3.2. Relative organ weights from piglets on day 22 of age.  Values 
represent means ± SD, n = 8 for Control and Diet a2; n = 7 for Diet a1.  
Pairwise comparisons determined using Student’s t-test.  Organ weights were 
similar for all dietary treatment groups. 
 
Tissue LCPUFA accretion  
 The FA composition of heart, liver, brain (cerebral cortex) and retina, 
harvested from pigs on day 22 of age is presented in Tables 3.4 and 3.5.  
Mean ARA levels in the brain, retina and heart were 10.97 ± 0.36%, 10.50 ± 
0.43%, 20.38 ± 0.82% of total FA, respectively, and were similar for all three 
dietary treatment groups.  ARA levels in the liver were 2% lower in pigs fed 
Diet a1 (17.33 ± 0.78% FA) compared with the Control (17.66 ± 0.49% FA), 
while the a2 pigs showed an intermediary liver ARA content (17.38 ± 0.57% 
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Table 3.3. Summary of hemogram and clinical chemistry parameters from 
piglets on day 21 of age1-2
Test Control a1 a2 P 
Hematocrit (%) 43 ± 3 46 ± 5 42 ± 2 NS 
Hemoglobin (g/dL) 13.2 ± 0.9 13.8 ± 1.3 12.9 ± 0.5 NS 
RBC (mill/μL) 6.3 ± 0.4 6.5 ± 0.5 6.3 ± 0.2 NS 
WBC (thou/μL) 10.5 ± 2.2 10.9 ± 1.3 9.9 ± 2.6 NS 
Lymphocytes (thou/μL) 6.1 ± 1.1 6.4 ± 1.1 5.7 ± 1.3 NS 
Platelet Count (thou/μL) 709 ± 76 697 ± 169 667 ± 136 NS 
Urea (mg/dL) 8 ± 2 8 ± 1 7 ± 2 NS 
Creatinine (mg/dL) 0.7 ± 0.2 0.7 ± 0.2 0.7 ± 0.1 NS 
Total Protein (g/dL) 4.6 ± 0.3 4.7 ± 0.2 4.5 ± 0.2 NS 
Albumin (g/dL) 3.6 ± 0.3 3.5 ± 0.2 3.5 ± 0.1 NS 
Globulin (g/dL) 1.0 ± 0.3 1.1 ± 0.3 1.1 ± 0.1 NS 
Glucose (mg/dL) 178 ± 37 165 ± 31 166 ± 33 NS 
AST (U/L) 37 ± 13a 28 ± 7b 25 ± 7b 0.01 
GGT (U/L) 23 ± 11 24 ± 14 24 ± 16 NS 
Creatine Kinase (U/L) 895 ± 520a 541 ± 227b 520 ± 228b 0.001
1Abbreviations: RBC, red blood cell count; WBC, white blood cell count; AST, 
aspartate aminotransferase; GGT, gamma-glutamyl transferase.  
 
2Values represent means ± SD, n = 8 per diet.  P < 0.05 indicates that all 
means are not equal; NS, not significant.  Pairwise comparisons determined 
using Student’s t-test; means not sharing a common superscript are 
significantly different (P < 0.05). 
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Table 3.4. FA composition of heart and liver from piglets fed one of three 
sources of ARA1
Diet Control a1 a2 P 
Heart FA (% total FA) 
    Σ SFA2 31.92 ± 0.29 32.15 ± 0.49 32.37 ± 0.39 NS 
    Σ MUFA 18.53 ± 0.75 18.35 ± 0.77 18.09 ± 0.74 NS 
    ARA 20.67 ± 0.56 19.93 ± 0.79 20.57 ± 0.93 NS 
    22:4n-6 0.92 ± 0.10 0.86 ± 0.09 0.83 ± 0.13 NS 
    22:5n-6 tr. tr. tr. n/a 
    Σ n-6 43.40 ± 0.86 43.44 ± 1.12 43.59 ± 1.00 NS 
    20:5n-3 0.42 ± 0.04 0.39 ± 0.03 0.39 ± 0.04 NS 
    22:5n-3 0.76 ± 0.08 0.71 ± 0.04 0.73 ± 0.05 NS 
    DHA 4.16 ± 0.39 4.04 ± 0.28 3.98 ± 0.35 NS 
    Σ n-3 6.05 ± 0.40 5.95 ± 0.31 5.85 ± 0.40 NS 
    ARA/DHA 5.00 ± 0.38 4.96 ± 0.40 5.22 ± 0.63 NS 
    Σ 22C HUFA3 5.84 ± 0.37 5.61 ± 0.34 5.53 ± 0.37 NS 
Liver        
    Σ SFA 42.15 ± 0.91 42.46 ± 0.57 41.89 ± 0.74 NS 
    Σ MUFA 13.64 ± 1.17 13.50 ± 0.71 13.89 ± 1.24 NS 
    ARA 17.66 ± 0.49a 17.33 ± 0.78b 17.38 ± 0.57ab 0.01 
    22:4n-6 0.64 ± 0.07 0.63 ± 0.10 0.65 ± 0.08 NS 
    22:5n-6 0.06 ± 0.01 0.06 ± 0.01 0.05 ± 0.02 NS 
    Σ n-6 34.10 ± 0.69 33.49 ± 0.59 34.17 ± 0.55 NS 
    20:5n-3 0.33 ± 0.04 0.28 ± 0.08 0.31 ± 0.05 NS 
    22:5n-3 1.03 ± 0.18 1.04 ± 0.13 1.04 ± 0.06 NS 
    DHA 7.70 ± 0.47b 8.23 ± 0.38a 7.62 ± 0.62b 0.046
    Σ n-3 9.80 ± 0.47 10.21 ± 0.43 9.70 ± 0.56 NS 
    ARA/DHA 2.30 ± 0.12 2.11 ± 0.12 2.29 ± 0.15 NS 
    Σ 22C HUFA 9.43 ± 0.52 9.96 ± 0.33 9.37 ± 0.68 NS 
1Values represent means ± SD, n = 8 per diet.  P < 0.05 indicates that all 
means are not equal; NS, not significant.  Pairwise comparisons determined 
using Student’s t-test; means not sharing a common superscript are 
significantly different (P < 0.05).  
 
2SFA, saturated FA; MUFA, monounsaturated FA. 
 
3∑ 22C HUFA = ∑ 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
 
 
66
 
 
 
Table 3.5. FA composition of brain (cerebral cortex) and retina from piglets fed 
one of three sources of ARA1
Diet Control a1 a2 P 
Cerebral cortex FA (% total FA) 
    ∑ SFA2 44.49 ± 0.58 44.82 ± 0.74 44.60 ± 0.42 NS 
    ∑ MUFA 20.63 ± 0.90 20.16 ± 1.06 20.28 ± 1.21 NS 
    22:3n-9 0.31 ± 0.05 0.31 ± 0.08 0.28 ± 0.04 NS 
    ARA 10.83 ± 0.34 11.04 ± 0.42 11.04 ± 0.33 NS 
    22:4n-6 3.99 ± 0.34 4.12 ± 0.38 4.20 ± 0.36 NS 
    22:5n-6 5.90 ± 0.50 5.82 ± 0.70 5.58 ± 0.57 NS 
    ∑ n-6 23.32 ± 0.73 23.62 ± 0.50 23.53 ± 0.80 NS 
    20:5n-3 0.12 ± 0.03 0.10 ± 0.04 0.12 ± 0.04 NS 
    22:5n-3 0.31 ± 0.04 0.31 ± 0.05 0.31 ± 0.04 NS 
    DHA 10.17 ± 0.71 9.97 ± 0.79 10.24 ± 0.39 NS 
    ∑ n-3 10.67 ± 0.70 10.48 ± 0.78 10.76 ± 0.41 NS 
    ARA/DHA 1.07 ± 0.08 1.11 ± 0.08 1.08 ± 0.04 NS 
    ∑ 22C HUFA3 20.67 ± 0.52 20.54 ± 0.60 20.62 ± 0.64 NS 
Retina           
    ∑ SFA 41.92 ± 0.92 42.65 ± 0.90 42.13 ± 1.19 NS 
    ∑ MUFA 17.64 ± 0.37 17.71 ± 0.52 17.83 ± 0.60 NS 
    22:3n-9 0.09  0.02 0.08  0.02 0.08  0.03 NS 
    ARA 10.45 ± 0.42 10.42 ± 0.43 10.63 ± 0.45 NS 
    22:4n-6 2.51 ± 0.19 2.45 ± 0.16 2.43 ± 0.11 NS 
    22:5n-6 2.58  0.41 2.41  0.56 2.36  0.41 NS 
    ∑ n-6 19.06 ± 0.85 18.90 ± 0.92 18.88 ± 0.68 NS 
    20:5n-3 0.46 ± 0.07 0.48 ± 0.09 0.40 ± 0.12 NS 
    22:5n-3 0.62 ± 0.07 0.64 ± 0.07 0.62 ± 0.06 NS 
    DHA 19.87 ± 0.65 19.20 ± 0.83 19.75 ± 1.66 NS 
    ∑ n-3 21.02 ± 0.69 20.38 ± 0.85 20.83 ± 1.76 NS 
    ARA/DHA 0.53 ± 0.02 0.54 ± 0.03 0.54 ± 0.05 NS 
    ∑ 22C HUFA 25.58 ± 0.90 24.70 ± 1.06 25.16 ± 1.58 NS 
1Values represent means ± SD, n = 8 per diet.  P < 0.05 indicates that all 
means are not equal; NS, not significant.  Pairwise comparisons determined 
using Student’s t-test; means not sharing a common superscript are 
significantly different (P < 0.05).  
 
2SFA, saturated FA; MUFA, monounsaturated FA. 
 
3∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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FA; P = 0.009).  Experimental diets equally supported DHA accretion in the 
brain, retina and heart, while in the liver, DHA levels were 7% higher in a1 pigs 
(8.23 ± 0.38) compared with the Control (7.70 ± 0.47% FA) and a2 (7.62 ± 
0.62% FA) groups (P = 0.046).  No other statistically significant differences in 
tissue FA accretion were observed among the dietary treatments. 
 Mean ARA levels in the RBC fraction were similar among all dietary 
treatment groups at every time point examined (days 3, 7, 14 and 21; Table 
3.6).  RBC DHA values were similar among dietary treatment groups on days 
3 and 21 of age, averaging 1.74 ± 0.32% and 2.57 ± 0.27% of total FA, 
respectively, but were significantly affected by diet on days 7 and 14 (Figure 
3.3).  On day 7 of age, RBC DHA levels were significantly higher in the a1 pigs 
(1.86 ± 0.19% FA) compared with a2 group (1.69 ± 0.26% FA), while Control 
pigs had intermediary levels (1.81 ± 0.27% FA; P = 0.03).  On day 14 of age, 
RBC DHA levels were the highest in the a1 pigs (2.85 ± 0.31% FA) and were 
similar between the Control (2.59 ± 0.37% FA) and a2 (2.49 ± 0.14% FA) 
groups (P = 0.02). 
 Mean RBC ARA, 20:5n-3, 22:5n-3, 22:4n-6 and 22:5n-6 were similar for 
all dietary treatment groups at every time point examined.  Because of this, 
treatment groups were pooled and linear regression analysis was performed to 
determine the temporal pattern of LCPUFA content in RBC.  Over the course 
of the experimental period, mean RBC ARA levels decreased from 6.98 ± 
0.60% of total FA on day 3 of age to 4.62 ± 0.32% FA on day 21 of age (P < 
0.0001; Figure 3.3).  Oneway analysis of RBC ARA content by day of age 
confirmed this temporal decline, with each incremental increase in age 
corresponding to a significant decrease in RBC ARA (P < 0.0001).  Mean RBC     
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Table 3.6. LCPUFA composition of RBC collected from piglets on days 3, 7, 
14 and 21 of life1
Diet Control a1 a2 P 
Day 3 FA (% total FA) 
ARA 7.06 ± 0.65 7.04 ± 0.67 6.84 ± 0.52 NS 
22:4n-6 0.97 ± 0.17 0.99 ± 0.14 1.00 ± 0.20 NS 
22:5n-6 1.96 ± 0.30 1.92 ± 0.12 1.84 ± 0.26 NS 
20:5n-3 0.16 ± 0.08 0.17 ± 0.11 0.14 ± 0.03 NS 
22:5n-3 0.49 ± 0.08 0.53 ± 0.19 0.49 ± 0.14 NS 
DHA 1.78 ± 0.37 1.70 ± 0.25 1.73 ± 0.36 NS 
Day 7         
ARA 5.94 ± 0.42 6.09 ± 0.47 5.76 ± 0.27 NS 
22:4n-6 0.72 ± 0.07 0.77 ± 0.08 0.69 ± 0.08 NS 
22:5n-6 1.09 ± 0.25 1.23 ± 0.10 1.03 ± 0.18 NS 
20:5n-3 0.16 ± 0.06 0.16 ± 0.06 0.14 ± 0.03 NS 
22:5n-3 0.50 ± 0.07 0.52 ± 0.08 0.48 ± 0.07 NS 
DHA 1.81 ± 0.27ab 1.86 ± 0.19a 1.69 ± 0.26b 0.03 
Day 14         
ARA 5.04 ± 0.48 5.32 ± 0.37 4.89 ± 0.22 NS 
22:4n-6 0.60 ± 0.08 0.61 ± 0.06 0.57 ± 0.03 NS 
22:5n-6 0.50 ± 0.05 0.54 ± 0.12 0.46 ± 0.08 NS 
20:5n-3 0.22 ± 0.06 0.22 ± 0.06 0.21 ± 0.03 NS 
22:5n-3 0.50 ± 0.06 0.55 ± 0.05 0.51 ± 0.04 NS 
DHA 2.59 ± 0.37b 2.85 ± 0.31a 2.49 ± 0.14b 0.02 
Day 21         
ARA 4.71 ± 0.39 4.55 ± 0.49 4.59 ± 0.23 NS 
22:4n-6 0.48 ± 0.06 0.50 ± 0.07 0.50 ± 0.07 NS 
22:5n-6 0.24 ± 0.05 0.25 ± 0.06 0.24 ± 0.05 NS 
20:5n-3 0.20 ± 0.09 0.18 ± 0.08 0.15 ± 0.09 NS 
22:5n-3 0.48 ± 0.05 0.47 ± 0.05 0.48 ± 0.04 NS 
DHA 2.61 ± 0.29 2.59 ± 0.26 2.52 ± 0.27 NS 
 
1Values represent means ± SD, n = 8 per diet.  P < 0.05 indicates that all 
means are not equal; NS, not significant.  Pairwise comparisons determined 
using Student’s t-test; means not sharing a common superscript are 
significantly different (P < 0.05). 
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Figure 3.3. Temporal pattern of ARA (A) and DHA (B) content in RBC 
collected from piglets on days 3, 7, 14 and 21 of life.  (A) represents linear 
regression analysis of RBC ARA content by age; each point corresponds to 
one pig.  In (B), values represent means ± SD, n = 8 per diet.  Pairwise 
comparisons determined using Student’s t-test; means not sharing a common 
superscript are significantly different (P < 0.05). 
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22:4n-6 (P < 0.0001) and 22:5n-6 (P < 0.0001) also decreased during the 
study, while 20:5n-3 and 22:5n-3 levels remained constant. 
 
Discussion 
 Preclinical studies with animals provide an invaluable tool for 
determining the safety of novel food additives for use in the diets of humans.  
In the present study, we evaluated two proprietary ARA oils for potential use in 
infant formula for toxicological effects and nutritional bioequivalence compared 
with a commercially available ARA source.  Domestic piglets were used 
because of their rapid rates of growth and similarities to humans in terms of 
brain development and metabolism of lipids and LCPUFA (22,23).   
 Growth performance is a well-accepted measure of health and vitality in 
developing infants.  In the present study, the two experimental ARA formulas 
were readily consumed and equally supported growth in the neonatal pigs 
compared with the Control formula.  Body weights were similar among the 
three dietary treatment groups at every time point and no differences were 
observed for organ weights upon sacrifice.  The 2000 Center for Disease 
Control growth charts show that human infants typically double their birth 
weight by 4 – 5 months of life and grow to 4 times their birth weight by 34 – 36 
months (24).  In comparison, our piglets grew to 4 times their initial body 
weight by day 22 of age.  This rapid rate of growth and concomitant high 
demand for formula suggests that any trace toxicological constituent of the 
formulas could have manifested as poorer growth or suboptimal clinical 
conditions during this short study duration.  Rather, pigs in this study appeared 
healthy and presented with few health ailments.  Loose stools in a number of 
piglets were the greatest concern during the first week of the study.  This was 
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likely caused by stresses from the transition period and adaptation to a new 
diet and environment (25), as opposed to a specific diet or dietary component. 
 Mean values for clinical chemistry and hemogram parameters were 
consistent with previous studies in neonatal pigs (26-28), and very few 
differences were observed among the three dietary treatment groups.  Control 
pigs showed elevated plasma AST and creatine kinase compared with pigs 
fed either of the experimental formulas.  For AST, a biomarker of tissue 
inflammation, Control values were within limits previously observed in nursery 
pigs (26) and weaned growing pigs (29), suggesting that the numerical 
difference among diets is likely biologically insignificant.  Creatine kinase 
levels were highest in the Control pigs compared with the two experimental 
ARA groups, although all treatment means were at the low end of the normal 
range for commercial pigs (30) and were comparable to values previously 
observed in a similar neonatal pig study (Chapter One).  In all pigs, liver 
sections were determined to be normal following pathohistological examination 
and showed no indication of gross abnormalities or toxicological changes.  
These results are consistent with other studies in pigs showing that the 
provision of an ARA-rich oil in the milk replacer formula up to 5x the level 
currently used in formula is safe and produces no adverse effect on serum 
clinical indicators or liver histology (27,31).  Thus, results from the present 
study indicate that the two experimental ARA oils produce no pathohistological 
abnormalities in the liver and have no adverse effect on clinical chemistry or 
hemogram parameters in rapidly growing piglets compared with the Control 
formula containing ARASCO. 
 The three ARA oils equally supported ARA accretion in the brain, retina 
and heart. On the other hand, liver ARA levels showed a remarkable 
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sensitivity to the dietary ARA content with the Control pigs having significantly 
higher ARA levels than the a1 group.  This discrepancy in liver ARA levels is 
consistent with the a1 diet providing 8% less ARA (0.62% vs. 0.67% total FA) 
than the Control and a2 diets, a difference that may arise from normal 
variability across product lots and over time during in the manufacturing 
process.  However, liver DHA levels also appeared responsive to the 
difference in dietary ARA level, with the a1 pigs having the highest DHA 
content.  Numerous studies have demonstrated a sensitivity of liver LCPUFA 
to dietary FA composition (32,33)(Chapter Two) that occurs primarily as a 
result of dietary FA composition but also due to the regulation of LCPUFA 
biosynthesis by dietary LCPUFA (34,35).  Overall, these results demonstrate 
that the experimental ARA oils are nutritionally bioequivalent to ARASCO and 
that subtle variations in total formula ARA content may influence liver ARA and 
DHA levels and endogenous LCPUFA biosynthesis. 
Studies with human infants are limited by the information they provide, 
especially with regard to the ethical limitations and potential risks associated 
with frequent blood sampling as well as the general unavailability of tissue 
from healthy individuals (36).  This study provided a unique opportunity to 
examine acute changes in RBC LCPUFA levels that may have been otherwise 
overlooked in clinical studies with infants.  The lack of significant differences 
among dietary treatment groups permitted pooling of sample means to 
determine the temporal pattern of RBC LCPUFA in pigs fed 0.64% ARA and 
0.32%.  Here, we observed significant decreases in RBC ARA, 22:4n-6 and 
22:5n-6 and an increase in RBC DHA compared with baseline values.  The 
rapid and dramatic decline in RBC ARA has not been previously documented 
in neonatal animals and the cause remains unclear.  Human infants that 
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consume breast milk or formula with added LCPUFA show a modest decline in 
RBC ARA during the first year of life (37).  At the same time, the infant brain 
rapidly accumulates ARA (4), and in Chapter Two, we demonstrated that the 
growing heart specifically incorporates and concentrates ARA, and that ARA 
accretion is limited by dietary ARA content.  It is probable that the temporal 
decline in RBC ARA we observed in the present study occurred as a result of 
rapid tissue ARA accretion.  With regard to DHA, we observed a general 
increase in RBC DHA that appeared to reach plateau by day 14 of age.  The 
low levels of RBC DHA may be explained by the negligible content of DHA in 
the sow milk previously analyzed from this herd (Chapters One and Two), 
while the content of RBC DHA on days 14 and 21 are consistent with most 
(38-41), but not all (42) studies of rapidly growing, neonatal pigs consuming 
low DHA. 
  In 2001, ARASCO was determined to be GRAS for use in term infant 
formula up to 1.88% of total fat and providing ARA up to 0.75% of total fat 
(12).  More recently, SUNTGA40S was determined to be GRAS for preterm 
and term infants when providing ARA up to 0.40% of total fat (14), and a third 
ARA-rich oil, RAO is currently pending FDA approval for use in infant formula 
(15).  It is possible that the experimental oils used in this study are 
SUNTGA40S, evaluated at a higher formula content than is currently approved 
for use in formula, and RAO which has not been reported in preclinical studies 
with neonatal pigs.  However, we cannot exclude the possibility that the 
experimental ARA oils are of a novel, proprietary formulation that may or may 
not be derived from M. alpina and for which little safety data is known. 
 Overall, this study evaluated the safety and bioefficacy of three 
ARA-rich oils for potential use in commercial infant formula.  Oils provided 
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ARA at 0.64% of total FA, were added with DHASCO to provide 0.34% DHA 
and resulted in no other major alterations in the formula FA composition.  We 
conclude that the two experimental ARA sources were nutritionally 
bioequivalent to ARASCO, each equally supporting ARA accretion in the brain, 
retina and heart, and produced no toxicological effects in neonatal pigs.  
Results further demonstrate that ARA-rich oils that deliver equivalent levels of 
ARA equally support the content of ARA in formula when prepared using a 
common manufacturing process. 
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Supplemental Figure 1. DHA tissue dose-response to dietary DHA with 
constant ARA (0.67% total FA).  Dietary DHA content for d1, d2 and d3 was 
0.32, 0.62 and 1.01% total FA, respectively.  Tissue DHA rises with dietary 
DHA in all tissues presented, (A) Heart, (B) Liver, (C) Brain (Cerebral cortex) 
and (D) Retina.  Each point represents one animal (n = 24 per panel).  P < 
0.05 indicates significant correlation between dietary DHA content and tissue 
DHA level; NS, not significant.  Student’s t-test used to determine significance 
of pairwise comparisons of mean tissue DHA content; means not sharing a 
common letter are significantly different (P < 0.05). 
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Supplemental Figure 2. Neural tissue DHA dose-response to dietary DHA with 
constant ARA (0.67% total FA).  Dietary DHA content for d1, d2 and d3 was 
0.32, 0.62 and 1.01% total FA, respectively.  Tissue DHA rises with dietary 
DHA in all tissues presented, (A) Cerebellum, (B) Hippocampus, (C) Globus 
pallidus and (D) Inferior colliculus. Mean DHA levels in Hippocampus, Globus 
pallidus and Inferior colliculus were 17%, 15% and 3% higher in d3 pigs 
compared with d1 pigs, although these differences were not statistically 
significant.  Each point represents one animal (n = 24 per panel).  P < 0.05 
indicates significant correlation between dietary DHA content and tissue DHA 
level; NS, not significant.  Student’s t-test used to determine significance of 
pairwise comparisons of mean tissue DHA content; means not sharing a 
common letter are significantly different (P < 0.05). 
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Supplemental Figure 3. Neural tissue DHA dose-response to dietary ARA 
content with constant DHA (1.0% total FA).  Dietary ARA content for a1, a2, a3 
and a4 was 0.09, 0.53, 0.69 and 1.06% total FA, respectively.  Increasing ARA 
had no effect on DHA levels in (A) Cerebellum, (B) Hippocampus, (C) Globus 
pallidus or (D) Inferior colliculus.  Each point represents one animal (n = 24 
per panel). P < 0.05 indicates significant correlation between dietary ARA 
content and tissue DHA level; NS, not significant.  Student’s t-test used to 
determine significance of pairwise comparisons of mean tissue DHA content; 
means not sharing a common letter are significantly different (P < 0.05). 
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Supplemental Table 1. FA composition of heart from piglets fed varying levels of ARA and DHA from days 3 - 28 of 
age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
Σ SFA 32.81 ± 1.00bc 32.16 ± 0.55c 32.63 ± 0.69bc 32.62 ± 0.62bc 32.64 ± 0.61ab 33.36 ± 0.90a 32.60 ± 0.66abc 0.006 
Σ MUFA 16.78 ± 1.05 17.74 ± 0.99 17.35 ± 1.05 17.50 ± 0.50 17.10 ± 0.88 17.59 ± 0.94 17.17 ± 0.75 NS 
ARA 14.76 ± 1.07d 18.57 ± 0.67c 19.41 ± 1.00b 20.90 ± 0.93a 19.98 ± 1.38ab 19.09 ± 1.88bc 20.26 ± 1.20ab <.0001 
22:4n-6 0.63 ± 0.09e 0.71 ± 0.09e 0.71 ± 0.06de 0.82 ± 0.09cd 0.88 ± 0.13bc 0.96 ± 0.12b 1.33 ± 0.13a <.0001 
22:5n-6 0.00 ± 0.01b 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 0.02 ± 0.03b 0.08 ± 0.01a <.0001 
Σ n-6 43.29 ± 1.09bc 42.95 ± 0.55c 43.45 ± 0.96bc 43.19 ± 0.77bc 44.12 ± 0.88b 44.06 ± 1.20b 46.85 ± 0.97a <.0001 
20:5n-3 0.75 ± 0.09a 0.54 ± 0.09b 0.49 ± 0.04b 0.41 ± 0.04c 0.42 ± 0.04c 0.32 ± 0.03d 0.28 ± 0.06d <.0001 
22:5n-3 0.59 ± 0.07d 0.59 ± 0.08d 0.57 ± 0.04d 0.57 ± 0.04d 0.71 ± 0.07c 0.83 ± 0.13b 1.24 ± 0.07a <.0001 
DHA 4.81 ± 0.24b 5.20 ± 0.49a 4.78 ± 0.43b 5.01 ± 0.25ab 4.20 ± 0.64c 3.00 ± 0.50d 0.75 ± 0.08e <.0001 
Σ n-3 6.58 ± 0.21ab 6.73 ± 0.57a 6.24 ± 0.42b 6.37 ± 0.31ab 5.71 ± 0.67c 4.57 ± 0.51d 2.48 ± 0.11e <.0001 
ARA/DHA 3.07 ± 0.19e 3.60 ± 0.39de 4.08 ± 0.34cd 4.18 ± 0.22cd 4.83 ± 0.58c 6.46 ± 0.78b 27.26 ± 3.17a <.0001 
∑ 22C HUFA4 6.04 ± 0.25bc 6.50 ± 0.51a 6.06 ± 0.4abc 6.40 ± 0.23ab 5.78 ± 0.72c 4.81 ± 0.59d 3.40 ± 0.15e <.0001 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Supplemental Table 2. FA composition of liver from piglets fed varying levels of ARA and DHA from days 3 – 28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
∑ SFA 42.89 ± 1.78 42.11 ± 0.44 42.88 ± 1.88 42.47 ± 2.23 42.29 ± 0.77 42.71 ± 1.62 39.97 ± 1.50 NS 
∑ MUFA 13.40 ± 1.08b 12.77 ± 1.11b 12.75 ± 0.83b 13.17 ± 0.99b 13.12 ± 0.77b 13.21 ± 0.68b 19.51 ± 3.80a <.0001 
20:4 (n-6) 13.92 ± 1.49d 16.14 ± 0.87c 16.12 ± 1.10bc 16.88 ± 1.50b 17.36 ± 0.63b 17.87 ± 1.46a 17.00 ± 1.36abc <.0001 
22:4 (n-6) 1.08 ± 0.29d 1.15 ± 0.22cd 1.27 ± 0.22c 1.36 ± 0.22bc 1.28 ± 0.20bc 1.50 ± 0.10b 2.27 ± 0.35a <.0001 
22:5 (n-6) 0.03 ± 0.06d 0.06 ± 0.05d 0.04 ± 0.04d 0.06 ± 0.07d 0.20 ± 0.09c 0.37 ± 0.11b 1.89 ± 0.53a <.0001 
∑ (n-6) 30.25 ± 1.10d 31.34 ± 0.58cd 31.57 ± 1.01bc 31.70 ± 1.34bc 32.58 ± 0.64b 34.05 ± 1.39a 35.16 ± 1.66a <.0001 
20:5 (n-3) 0.61 ± 0.14a 0.42 ± 0.15bc 0.45 ± 0.10b 0.36 ± 0.11cd 0.34 ± 0.05cd 0.31 ± 0.04d 0.18 ± 0.06e <.0001 
22:5 (n-3) 0.94 ± 0.11c 0.91 ± 0.09c 0.94 ± 0.12c 0.94 ± 0.14c 1.01 ± 0.07c 1.11 ± 0.16b 1.35 ± 0.20a <.0001 
22:6 (n-3) 10.77 ± 1.77a 11.43 ± 1.22a 10.49 ± 1.41a 10.45 ± 1.79a 9.65 ± 1.01b 7.52 ± 0.69c 2.37 ± 0.30d <.0001 
∑ (n-3) 12.67 ± 1.79a 13.08 ± 1.15a 12.22 ± 1.57a 12.11 ± 1.90a 11.34 ± 1.10b 9.29 ± 0.76c 4.13 ± 0.49d <.0001 
ARA/DHA 1.31 ± 0.17f 1.43 ± 0.19ef 1.55 ± 0.16de 1.65 ± 0.24cd 1.82 ± 0.21c 2.39 ± 0.20b 7.21 ± 0.42a <.0001 
∑ 22C HUFA4 12.82 ± 1.86a 13.55 ± 1.26a 12.74 ± 1.44ab 12.81 ± 1.90ab 12.14 ± 1.21b 10.51 ± 0.81c 7.88 ± 1.22d <.0001 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Supplemental Table 3. FA composition of cerebral cortex from piglets fed varying levels of ARA and DHA from days 3 – 
28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
∑ SFA 45.67 ± 0.53ab 45.77 ± 0.81ab 46.10 ± 0.90a 46.04 ± 1.10a 45.27 ± 0.74bc 45.93 ± 0.79a 44.14 ± 0.64c 0.005 
∑ MUFA 18.55 ± 0.53bc 18.87 ± 0.75bc 18.34 ± 0.67c 18.27 ± 0.77c 18.70 ± 0.44bc 18.95 ± 0.76b 19.97 ± 0.93a 0.006 
22:3n-9 0.23 ± 0.06b 0.21 ± 0.03b 0.21 ± 0.02b 0.22 ± 0.06b 0.23 ± 0.04b 0.19 ± 0.03b 0.31 ± 0.00a 0.009 
20:4n-6 11.95 ± 0.29 11.82 ± 0.60 11.80 ± 0.35 12.04 ± 0.63 11.93 ± 0.40 11.77 ± 0.68 12.33 ± 0.00 NS 
22:4n-6 4.03 ± 0.52 4.06 ± 0.16 4.09 ± 0.35 4.21 ± 0.60 4.21 ± 0.32 4.19 ± 0.26 4.81 ± 0.30 NS 
22:5n-6 4.49 ± 0.40c 4.44 ± 0.47c 4.68 ± 0.29c 4.61 ± 0.56c 5.52 ± 0.64b 5.49 ± 0.25b 8.26 ± 0.18a <.0001 
∑ n-6 22.58 ± 0.77d 22.36 ± 1.03d 22.54 ± 0.92d 22.78 ± 1.40cd 23.65 ± 0.85bc 23.56 ± 0.80b 27.62 ± 0.50a <.0001 
20:5n-3 0.06 ± 0.01b 0.06 ± 0.02b 0.06 ± 0.02b 0.07 ± 0.01b 0.05 ± 0.02b 0.06 ± 0.02b 0.11 ± 0.03a 0.005 
22:5n-3 0.20 ± 0.02c 0.19 ± 0.02c 0.19 ± 0.04c 0.19 ± 0.03c 0.20 ± 0.02c 0.25 ± 0.05b 0.32 ± 0.03a <.0001 
22:6n-3 12.10 ± 0.83a 11.91 ± 0.74ab 11.98 ± 0.69ab 11.90 ± 0.69ab 11.30 ± 0.70b 10.56 ± 0.67c 6.88 ± 0.55d <.0001 
∑ n-3 12.36 ± 0.84a 12.16 ± 0.76ab 12.23 ± 0.71ab 12.16 ± 0.69ab 11.55 ± 0.72b 10.87 ± 0.67c 7.31 ± 0.55d <.0001 
ARA/DHA 0.99 ± 0.07c 1.00 ± 0.09c 0.99 ± 0.05c 1.02 ± 0.10bc 1.06 ± 0.09bc 1.12 ± 0.11b 1.80 ± 0.17a <.0001 
∑ 22C HUFA4 20.82 ± 0.81 20.60 ± 0.61 20.94 ± 1.01 20.91 ± 0.99 21.23 ± 0.88 20.49 ± 0.79 20.27 ± 0.72 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Supplemental Table 4. FA composition of retina from piglets fed varying levels of ARA and DHA from days 3 – 28 of 
age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
Σ SFA 44.70 ± 0.83 44.39 ± 0.51 44.89 ± 0.97 44.63 ± 0.91 44.40 ± 1.13 44.57 ± 0.69 43.61 ± 0.32 NS 
Σ MUFA 18.40 ± 0.59 18.38 ± 0.37 18.48 ± 0.57 18.24 ± 0.65 18.63 ± 0.71 18.72 ± 0.43 19.50 ± 0.70 NS 
22:3n-9 0.10 ± 0.03 0.11 ± 0.02 0.10 ± 0.02 0.10 ± 0.10 0.13 ± 0.02 0.11 ± 0.03 0.12 ± 0.02 NS 
20:4n-6 9.48 ± 0.23c 9.70 ± 0.61bc 9.66 ± 0.32bc 9.81 ± 0.31b 9.96 ± 0.37b 9.95 ± 0.25b 10.74 ± 0.50a 0.0004 
22:4n-6 1.66 ± 0.15e 1.72 ± 0.12de 1.77 ± 0.12d 1.81 ± 0.17d 1.98 ± 0.19c 2.13 ± 0.12b 2.98 ± 0.17a <.0001 
22:5n-6 1.48 ± 0.30d 1.48 ± 0.32d 1.45 ± 0.16d 1.55 ± 0.30d 2.03 ± 0.64c 2.29 ± 0.26b 5.24 ± 0.39a <.0001 
Σ n-6 15.31 ± 0.54d 15.42 ± 0.89d 15.41 ± 0.47d 15.57 ± 0.70d 16.37 ± 0.91c 16.98 ± 0.24b 21.65 ± 0.96a <.0001 
20:5n-3 0.18 ± 0.05ab 0.15 ± 0.04b 0.18 ± 0.05a 0.13 ± 0.02c 0.10 ± 0.04c 0.08 ± 0.02d 0.02 ± 0.01e <.0001 
22:5n-3 0.64 ± 0.04a 0.60 ± 0.05b 0.63 ± 0.06ab 0.60 ± 0.03b 0.55 ± 0.03c 0.60 ± 0.05b 0.60 ± 0.05abc 0.0001 
22:6n-3 20.42 ± 1.20ab 20.70 ± 0.54a 20.07 ± 1.47ab 20.49 ± 1.31ab 19.50 ± 1.50bc 18.68 ± 0.96c 14.16 ± 1.37d <.0001 
Σ n-3 21.24 ± 1.22ab 21.44 ± 0.57a 20.89 ± 1.48ab 21.22 ± 1.34ab 20.15 ± 1.55bc 19.36 ± 0.99c 14.78 ± 1.36d <.0001 
ARA/DHA 0.47 ± 0.03c 0.47 ± 0.04c 0.48 ± 0.04c 0.48 ± 0.04bc 0.51 ± 0.04bc 0.53 ± 0.03b 0.77 ± 0.11a <.0001 
∑ 22C HUFA4 24.29 ± 1.34 24.61 ± 0.49 24.03 ± 1.49 24.55 ± 1.48 24.20 ± 1.31 23.81 ± 0.90 23.10 ± 0.98 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Supplemental Table 5. FA composition of cerebellum from piglets fed varying levels of ARA and DHA from days 3 – 28 
of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
Σ SFA 41.83 ± 1.91 42.29 ± 2.00 42.72 ± 1.43 42.12 ± 1.93 42.41 ± 1.66 42.40 ± 2.31 41.57 ± 0.85 NS 
Σ MUFA 27.22 ± 0.99 26.93 ± 1.50 25.95 ± 1.04 27.07 ± 1.30 26.35 ± 1.60 25.98 ± 2.60 27.20 ± 1.43 NS 
22:3n-9 0.42 ± 0.07abc 0.38 ± 0.05c 0.37 ± 0.04c 0.37 ± 0.04c 0.44 ± 0.04ab 0.38 ± 0.07bc 0.48 ± 0.06a 0.009 
20:4n-6 10.40 ± 0.30c 10.76 ± 0.26bc 11.03 ± 0.31ab 10.44 ± 0.44c 10.95 ± 0.62ab 10.78 ± 0.43bc 11.48 ± 0.73a 0.007 
22:4n-6 3.29 ± 0.41d 3.23 ± 0.38d 3.39 ± 0.32cd 3.43 ± 0.32cd 3.55 ± 0.19c 3.97 ± 0.25b 4.66 ± 0.31a <.0001 
22:5n-6 2.12 ± 0.26cd 2.19 ± 0.34d 2.18 ± 0.19cd 2.17 ± 0.26d 2.70 ± 0.37bc 3.34 ± 1.09b 4.82 ± 0.23a <.0001 
Σ n-6 17.98 ± 1.09d 18.15 ± 1.17d 18.47 ± 0.84cd 18.07 ± 0.64d 19.22 ± 0.65c 20.27 ± 1.12b 23.26 ± 0.92a <.0001 
20:5n-3 0.21 ± 0.03 0.22 ± 0.04 0.20 ± 0.05 0.22 ± 0.05 0.20 ± 0.06 0.20 ± 0.07 0.21 ± 0.05 NS 
22:5n-3 0.35 ± 0.06bc 0.31 ± 0.05cd 0.32 ± 0.05cd 0.32 ± 0.05d 0.31 ± 0.02cd 0.36 ± 0.05b 0.47 ± 0.04a <.0001 
22:6n-3 11.29 ± 1.61a 11.08 ± 1.68a 11.29 ± 1.19a 11.19 ± 1.44a 10.37 ± 0.75ab 9.83 ± 0.76b 6.10 ± 0.28c <.0001 
Σ n-3 11.85 ± 1.67a 11.61 ± 1.71a 11.82 ± 1.21a 11.73 ± 1.47a 10.88 ± 0.79ab 10.39 ± 0.81b 6.77 ± 0.28c <.0001 
ARA/DHA 0.91 ± 0.09d 0.96 ± 0.11d 0.97 ± 0.07cd 0.95 ± 0.11cd 1.06 ± 0.12bc 1.10 ± 0.09b 1.89 ± 0.20a <.0001 
∑ 22C HUFA4 17.47 ± 1.79 17.19 ± 2.23 17.56 ± 1.51 17.47 ± 1.54 17.36 ± 0.70 17.88 ± 1.37 16.53 ± 0.30 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Supplemental Table 6. FA composition of hippocampus from piglets fed varying levels of ARA and DHA from days 3 – 
28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
∑ SFA 41.80 ± 1.32abc 42.33 ± 1.12ab 41.48 ± 1.62c 41.13 ± 1.76bc 42.51 ± 0.94ab 41.53 ± 1.34bc 43.67 ± 0.520a 0.046 
∑ MUFA 26.65 ± 3.10 25.62 ± 3.24 27.02 ± 4.01 27.44 ± 5.57 24.75 ± 2.42 26.92 ± 3.89 23.67 ± 1.48 NS 
22:3n-9 0.48 ± 0.08 0.46 ± 0.12 0.49 ± 0.12 0.45 ± 0.09 0.46 ± 0.10 0.52 ± 0.15 0.47 ± 0.12 NS 
20:4n-6 10.40 ± 0.89 10.78 ± 0.93 10.57 ± 1.09 10.61 ± 1.57 11.10 ± 0.97 10.85 ± 1.23 11.77 ± 0.96 NS 
22:4n-6 4.57 ± 0.36 4.68 ± 0.43 4.63 ± 0.57 4.72 ± 0.63 4.78 ± 0.44 5.03 ± 0.51 5.37 ± 0.43 NS 
22:5n-6 2.89 ± 0.22c 2.96 ± 0.39c 3.06 ± 0.39cd 2.68 ± 0.67d 3.71 ± 0.40b 3.31 ± 0.53bc 5.58 ± 0.60a <.0001 
∑ n-6 20.27 ± 1.21c 20.62 ± 1.26bc 20.46 ± 1.85c 20.09 ± 2.66bc 21.64 ± 1.40b 21.47 ± 1.94b 24.83 ± 0.99a 0.0001 
20:5n-3 0.30 ± 0.14 0.26 ± 0.11 0.32 ± 0.15 0.32 ± 0.21 0.25 ± 0.10 0.29 ± 0.11 0.21 ± 0.05 NS 
22:5n-3 0.24 ± 0.03ab 0.22 ± 0.05bc 0.22 ± 0.02bc 0.20 ± 0.05bc 0.19 ± 0.02c 0.24 ± 0.04ab 0.27 ± 0.04a 0.009 
22:6n-3 9.89 ± 0.26a 9.74 ± 1.43a 9.66 ± 0.68ab 9.63 ± 1.73a 9.44 ± 1.03a 8.27 ± 1.48b 6.12 ± 0.68c 0.0002 
∑ n-3 9.74 ± 1.15ab 9.96 ± 1.45ab 9.45 ± 1.36bc 9.83 ± 1.78a 9.64 ± 1.05ab 8.50 ± 1.50c 6.39 ± 0.70d <.0001 
ARA/DHA 1.10 ± 0.09c 1.12 ± 0.13c 1.16 ± 0.18c 1.11 ± 0.09c 1.18 ± 0.07c 1.33 ± 0.14b 1.93 ± 0.18a <.0001 
∑ 22C HUFA4 17.20 ± 1.41 17.60 ± 1.87 17.13 ± 1.99 17.23 ± 2.89 18.12 ± 1.44 16.84 ± 2.23 17.34 ± 0.64 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Supplemental Table 7. FA composition of globus pallidus from piglets fed varying levels of ARA and DHA from days 3 – 
28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
∑ SFA 42.71 ± 1.41 41.00 ± 2.51 42.24 ± 1.05 41.98 ± 1.42 41.56 ± 1.54 41.65 ± 2.00 42.67 ± 1.93 NS 
∑ MUFA 27.27 ± 2.77 31.99 ± 6.70 28.36 ± 2.42 29.79 ± 3.98 30.05 ± 4.63 29.86 ± 4.61 26.74 ± 3.75 NS 
22:3n-9 0.42 ± 0.08 0.47 ± 0.11 0.47 ± 0.06 0.50 ± 0.10 0.50 ± 0.09 0.48 ± 0.11 0.50 ± 0.09 NS 
20:4n-6 10.33 ± 0.68 9.33 ± 1.28 10.07 ± 0.44 9.92 ± 0.76 10.02 ± 0.88 10.09 ± 0.96 10.73 ± 0.82 NS 
22:4n-6 3.81 ± 0.32bc 3.59 ± 0.73b 4.25 ± 0.51ab 3.98 ± 0.87bc 3.72 ± 0.37bc 4.04 ± 0.58bc 4.78 ± 0.65a 0.02 
22:5n-6 2.93 ± 0.37b 2.24 ± 0.77c 2.81 ± 0.40bc 2.64 ± 0.58bc 3.16 ± 0.73b 3.04 ± 0.78b 5.40 ± 0.92a <.0001 
∑ n-6 18.93 ± 1.02b 17.00 ± 2.41c 18.82 ± 1.15bc 18.18 ± 1.93bc 18.59 ± 1.65bc 18.99 ± 1.88b 22.72 ± 2.22a 0.0002 
20:5n-3 0.35 ± 0.11 0.54 ± 0.31 0.39 ± 0.15 0.45 ± 0.17 0.48 ± 0.20 0.44 ± 0.19 0.33 ± 0.15 NS 
22:5n-3 0.15 ± 0.12 0.12 ± 0.04 0.13 ± 0.03 0.13 ± 0.02 0.11 ± 0.04 0.14 ± 0.06 0.19 ± 0.06 NS 
22:6n-3 9.45 ± 0.97a 8.09 ± 2.61ab 8.80 ± 0.94ab 8.18 ± 1.36ab 7.91 ± 1.95b 7.66 ± 1.68bc 6.08 ± 0.35c 0.01 
∑ n-3 9.96 ± 0.89a 8.75 ± 2.34ab 9.33 ± 0.88ab 8.76 ± 1.23ab 8.50 ± 1.79b 8.25 ± 1.57b 6.60 ± 0.29c 0.005 
ARA/DHA 1.10 ± 0.07d 1.24 ± 0.30bcd 1.15 ± 0.11cd 1.23 ± 0.15bcd 1.32 ± 0.26bc 1.37 ± 0.30b 1.77 ± 0.15a <.0001 
∑ 22C HUFA4 16.74 ± 1.12 14.49 ± 3.72 16.44 ± 1.37 15.41 ± 2.20 15.37 ± 2.68 15.34 ± 2.50 16.92 ± 1.43 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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Supplemental Table 8. FA composition of inferior colliculus from piglets fed varying levels of ARA and DHA from days 3 
– 28 of age1
Diet a1 a2 a3-d3 a4 d2 d1 MR2   
ARA/DHA3 0.09/1.00 0.53/1.02 0.69/1.01 1.06/1.04 0.67/0.62 0.66/0.33 0.74/0.01 P 
 FA (% total FA) 
∑ SFA 40.88 ± 1.24 41.85 ± 1.15 41.59 ± 1.62 40.66 ± 1.38 41.45 ± 1.16 41.52 ± 1.28 40.94 ± 1.87 NS 
∑ MUFA 30.94 ± 2.12 30.92 ± 3.15 30.08 ± 3.70 32.32 ± 2.74 30.81 ± 1.93 29.83 ± 2.49 31.02 ± 4.44 NS 
22:3n-9 0.33 ± 0.04bc 0.30 ± 0.04c 0.29 ± 0.06c 0.37 ± 0.07b 0.32 ± 0.07bc 0.29 ± 0.04c 0.48 ± 0.10a <.0001 
20:4n-6 8.58 ± 0.35 8.55 ± 0.75 8.85 ± 0.84 8.61 ± 0.52 8.63 ± 0.50 8.97 ± 0.73 9.45 ± 1.25 NS 
22:4n-6 3.54 ± 0.21b 3.36 ± 0.19b 3.55 ± 0.31b 3.56 ± 0.29b 3.42 ± 0.30b 3.70 ± 0.35b 4.68 ± 1.16a <.0001 
22:5n-6 1.58 ± 0.49bc 1.50 ± 0.35c 1.60 ± 0.45bc 1.62 ± 0.52bc 1.93 ± 0.53b 1.91 ± 0.32b 3.76 ± 0.45a <.0001 
∑ n-6 15.97 ± 0.56b 15.53 ± 1.04b 16.12 ± 1.24b 15.86 ± 0.93b 16.14 ± 1.03b 16.77 ± 1.13b 19.93 ± 2.37a <.0001 
20:5n-3 0.39 ± 0.07 0.35 ± 0.12 0.34 ± 0.11 0.43 ± 0.09 0.36 ± 0.05 0.33 ± 0.07 0.39 ± 0.14 NS 
22:5n-3 0.19 ± 0.02ab 0.18 ± 0.04abc 0.19 ± 0.04ab 0.15 ± 0.02c 0.16 ± 0.03bc 0.18 ± 0.03bc 0.21 ± 0.06a 0.02 
22:6n-3 10.71 ± 0.94a 10.32 ± 1.88a 10.84 ± 1.50a 9.58 ± 1.21a 10.18 ± 1.27a 10.53 ± 0.85a 6.27 ± 1.14b <.0001 
∑ n-3 11.29 ± 0.92a 10.85 ± 1.83a 11.37 ± 1.46a 10.17 ± 1.15a 10.70 ± 1.25a 11.04 ± 0.82a 6.87 ± 1.07b <.0001 
ARA/DHA 0.81 ± 0.06b 0.84 ± 0.11b 0.82 ± 0.08b 0.91 ± 0.10b 0.86 ± 0.09b 0.85 ± 0.06b 1.55 ± 0.32a 0.0001 
 ∑ 22C HUFA4 16.35 ± 1.10 15.66 ± 2.18 16.46 ± 2.03 15.28 ± 1.60 16.02 ± 1.46 16.61 ± 1.23 15.40 ± 1.74 NS 
 
1Values represent mean ± SD, n = 8 per diet.    P < 0.05 indicates that all means are not equal; NS, not significant.  
Pairwise comparisons determined using Student’s t-test; means not sharing a common superscript are significantly 
different (P < 0.05).  
 
2ARA/DHA, dietary content of ARA/DHA (% FA/FA). 
 
3SFA, saturated FA, MUFA, monounsaturated FA. 
 
4∑ 22C HUFA = ∑ 22:3n-9, 22:4n-6, 22:5n-6, 22:5n-3, DHA. 
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APPENDIX II 
 
ONE-STEP HYDROLYSIS, EXTRACTION AND METHYLATION 
PROCEDURE FOR THE PREPARATION OF FATTY ACID METHYL 
ESTERS FROM VERTEBRATE SOFT TISSUE 
 
This procedure is adapted from the One-step procedure of Garces and 
Mancha (1993). 
 
Reagents: 
Aqueous Reagent:  
Methanol 
2,2-Dimethoxypropane 
Concentrated sulfuric acid  
(85:11:4 by volume)  
 
Organic Reagent:  
Heptane  
Toluene  
(63:37 by volume)  
 
Heptane 
Saturated sodium chloride 
Di-17:0 phosphatidylcholine, 5.65 ug/ul concentration for internal standard 
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Protocol:  
1. Weigh out sample (~ 50mg)1 in a 16 x 125 mm test tube.  
2. Add internal standard, total amount based on sample type. 
 
3. Add 2 mL heptane. 
 
4. Add 1.4 mL of the aqueous reagent and 1.6 mL of the organic reagent with 
a glass pipette.  
 
5. Seal cap inside and out with Teflon tape and vortex for 1 min.  
 
6. Place tubes in a heating block at 80°C for two hours.  
 
7. Vortex tubes until they come to room temperature (~10 min).  
 
8. Add 2 mL of saturated sodium chloride and vortex.  
 
9. Centrifuge for 10 min at 3500 rpm.  
 
10. Transfer top layer to a clean test tube (to be dried down). 
 
11. Add 2 mL of heptane to sample tube.  
 
12. Vortex for 1 min followed by centrifugation for 10 min at 3500 rpm. 
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13. Transfer top layer to the clean tube (to be dried down). 
 
14. Evaporate fatty acid methyl esters (FAME) + heptane (in clean tube) under 
nitrogen. 
 
15. Resolubilize FAME in 200 μL helptane. 
 
16. Transfer FAME to GC vial for storage. 
 
 
150 mg of tissue is preferred weight.  Alternatively, up to 50 μL of aqueous 
sample (e.g. plasma, milk, red blood cells) may be used.  Samples suspended 
in a greater volume of aqueous solution must first be dried using a Speed Vac 
concentrator. 
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